[{"data":1,"prerenderedAt":839},["ShallowReactive",2],{"navigation":3,"$ftllyK3V5-afaQaAPZIlN_0chD_JZw143fa-VS_B--kw":48,"$fQ1XKc23FMycqAzryW-beJBK11fZIURw5v93oI1r_GA8":774},[4,23],{"title":5,"path":6,"stem":7,"children":8,"icon":22},"Getting Started","\u002Fdocs\u002Fgetting-started","1.docs\u002F1.getting-started\u002F1.index",[9,12,17],{"title":10,"path":6,"stem":7,"icon":11},"Introduction","i-lucide-house",{"title":13,"path":14,"stem":15,"icon":16},"Installation","\u002Fdocs\u002Fgetting-started\u002Finstallation","1.docs\u002F1.getting-started\u002F2.installation","i-lucide-download",{"title":18,"path":19,"stem":20,"icon":21},"Usage","\u002Fdocs\u002Fgetting-started\u002Fusage","1.docs\u002F1.getting-started\u002F3.usage","i-lucide-sliders",false,{"title":24,"path":25,"stem":26,"children":27,"page":22},"Essentials","\u002Fdocs\u002Fessentials","1.docs\u002F2.essentials",[28,33,38,43],{"title":29,"path":30,"stem":31,"icon":32},"Markdown Syntax","\u002Fdocs\u002Fessentials\u002Fmarkdown-syntax","1.docs\u002F2.essentials\u002F1.markdown-syntax","i-lucide-heading-1",{"title":34,"path":35,"stem":36,"icon":37},"Code Blocks","\u002Fdocs\u002Fessentials\u002Fcode-blocks","1.docs\u002F2.essentials\u002F2.code-blocks","i-lucide-code-xml",{"title":39,"path":40,"stem":41,"icon":42},"Prose Components","\u002Fdocs\u002Fessentials\u002Fprose-components","1.docs\u002F2.essentials\u002F3.prose-components","i-lucide-component",{"title":44,"path":45,"stem":46,"icon":47},"Images and Embeds","\u002Fdocs\u002Fessentials\u002Fimages-embeds","1.docs\u002F2.essentials\u002F4.images-embeds","i-lucide-image",[49,164,232,288,347,400,458,519,581,646,710],{"id":50,"name":51,"slug":52,"permalink":53,"date_created":54,"date_created_gmt":54,"date_modified":55,"date_modified_gmt":55,"type":56,"status":57,"featured":22,"catalog_visibility":58,"description":59,"short_description":60,"sku":61,"price":62,"regular_price":59,"sale_price":59,"date_on_sale_from":63,"date_on_sale_from_gmt":63,"date_on_sale_to":63,"date_on_sale_to_gmt":63,"on_sale":22,"purchasable":64,"total_sales":65,"virtual":22,"downloadable":22,"downloads":66,"download_limit":67,"download_expiry":67,"external_url":59,"button_text":59,"tax_status":68,"tax_class":59,"manage_stock":64,"stock_quantity":69,"backorders":70,"backorders_allowed":22,"backordered":22,"low_stock_amount":63,"sold_individually":22,"weight":59,"dimensions":71,"shipping_required":64,"shipping_taxable":64,"shipping_class":59,"shipping_class_id":72,"reviews_allowed":64,"average_rating":73,"rating_count":72,"upsell_ids":74,"cross_sell_ids":75,"parent_id":72,"purchase_note":59,"categories":76,"brands":81,"tags":82,"images":83,"attributes":93,"default_attributes":98,"variations":100,"grouped_products":102,"menu_order":72,"price_html":103,"related_ids":104,"meta_data":110,"stock_status":149,"has_options":64,"post_password":59,"global_unique_id":59,"jetpack_sharing_enabled":64,"_links":150},3078,"Ipamorelin","ipamorelin","https:\u002F\u002Fapi.tlpeptides.com\u002Fproduct\u002Fipamorelin\u002F","2026-02-06T18:39:26","2026-05-20T00:01:46","variable","publish","visible","","\u003Cp>\u003Cstrong>NOT INTENDED FOR HUMAN OR ANIMAL USE\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>\u003Cstrong>⚠️ Intended strictly for research purposes only.\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cp>This research compound is provided in \u003Cstrong>lyophilized form\u003C\u002Fstrong> and packaged in a \u003Cstrong>3ml vial\u003C\u002Fstrong> to ensure stability and reliable handling. Our products are prepared for research settings that require precise materials for controlled studies.\u003C\u002Fp>\n\u003Cul data-start=\"399\" data-end=\"598\">\n\u003Cli data-start=\"399\" data-end=\"460\">\n\u003Cp data-start=\"401\" data-end=\"460\">Supplied as \u003Cstrong data-start=\"413\" data-end=\"435\">lyophilized powder\u003C\u002Fstrong> for extended stability\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli data-start=\"399\" data-end=\"460\">Certificate of Analysis \u003Cstrong>(COA)\u003C\u002Fstrong> is provided for verification\u003C\u002Fli>\n\u003Cli data-start=\"461\" data-end=\"497\">\n\u003Cp data-start=\"463\" data-end=\"497\">Packaged in a \u003Cstrong data-start=\"477\" data-end=\"495\">3ml vial\u003C\u002Fstrong>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli data-start=\"540\" data-end=\"598\">\n\u003Cp data-start=\"542\" data-end=\"598\">Suitable for a variety of \u003Cstrong>laboratory research studies\u003C\u002Fstrong>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003C\u002Ful>\n","TLP-IPA-10MG","60",null,true,7,[],-1,"taxable",9,"no",{"length":59,"width":59,"height":59},0,"0.00",[],[],[77],{"id":78,"name":79,"slug":80},15,"Products","products",[],[],[84],{"id":85,"date_created":86,"date_created_gmt":86,"date_modified":87,"date_modified_gmt":87,"src":88,"name":89,"alt":59,"srcset":90,"sizes":91,"thumbnail":92},3050,"2026-02-03T22:56:21","2026-05-20T00:01:58","https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2026\u002F02\u002FpeptideBottleTL.png","peptideBottleTL","https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2026\u002F02\u002FpeptideBottleTL-66x66.png 66w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2026\u002F02\u002FpeptideBottleTL-150x150.png 150w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2026\u002F02\u002FpeptideBottleTL-200x200.png 200w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2026\u002F02\u002FpeptideBottleTL-276x276.png 276w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2026\u002F02\u002FpeptideBottleTL-300x300.png 300w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2026\u002F02\u002FpeptideBottleTL-400x400.png 400w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2026\u002F02\u002FpeptideBottleTL-500x500.png 500w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2026\u002F02\u002FpeptideBottleTL-600x600.png 600w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2026\u002F02\u002FpeptideBottleTL-700x700.png 700w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2026\u002F02\u002FpeptideBottleTL-768x768.png 768w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2026\u002F02\u002FpeptideBottleTL-800x800.png 800w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2026\u002F02\u002FpeptideBottleTL.png 1024w","(max-width: 1024px) 100vw, 1024px","https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2026\u002F02\u002FpeptideBottleTL-500x500.png",[94],{"id":72,"name":95,"slug":95,"position":72,"visible":64,"variation":64,"options":96},"Size",[97],"10mg",[99],{"id":72,"name":95,"option":97},[101],3080,[],"\u003Cspan class=\"woocommerce-Price-amount amount\">\u003Cbdi>\u003Cspan class=\"woocommerce-Price-currencySymbol\">$\u003C\u002Fspan>60.00\u003C\u002Fbdi>\u003C\u002Fspan>",[105,106,107,108,109],2954,2827,2777,2926,3075,[111,115,117,119,121,123,125,132,136,139,143,147],{"id":112,"key":113,"value":114},10870,"rank_math_internal_links_processed","1",{"id":116,"key":113,"value":114},10889,{"id":118,"key":113,"value":114},10890,{"id":120,"key":113,"value":114},10891,{"id":122,"key":113,"value":114},10892,{"id":124,"key":113,"value":114},10893,{"id":126,"key":127,"value":128},10894,"_fusion",{"slider_visibility":129,"slider_type":70,"wooslider":130,"page_title_bar":131},"small-visibility,medium-visibility,large-visibility","0","default",{"id":133,"key":134,"value":135},10895,"avada_post_views_count","106",{"id":137,"key":138,"value":114},10896,"avada_today_post_views_count",{"id":140,"key":141,"value":142},10897,"avada_post_views_count_today_date","21-05-2026",{"id":144,"key":145,"value":146},10898,"rank_math_seo_score","8",{"id":148,"key":113,"value":114},10899,"instock",{"self":151,"collection":161},[152],{"href":153,"targetHints":154},"https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-json\u002Fwc\u002Fv3\u002Fproducts\u002F3078",{"allow":155},[156,157,158,159,160],"GET","POST","PUT","PATCH","DELETE",[162],{"href":163},"https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-json\u002Fwc\u002Fv3\u002Fproducts",{"id":109,"name":165,"slug":166,"permalink":167,"date_created":168,"date_created_gmt":168,"date_modified":169,"date_modified_gmt":169,"type":56,"status":57,"featured":22,"catalog_visibility":58,"description":59,"short_description":60,"sku":170,"price":171,"regular_price":59,"sale_price":59,"date_on_sale_from":63,"date_on_sale_from_gmt":63,"date_on_sale_to":63,"date_on_sale_to_gmt":63,"on_sale":22,"purchasable":64,"total_sales":69,"virtual":22,"downloadable":22,"downloads":172,"download_limit":67,"download_expiry":67,"external_url":59,"button_text":59,"tax_status":68,"tax_class":59,"manage_stock":64,"stock_quantity":72,"backorders":70,"backorders_allowed":22,"backordered":22,"low_stock_amount":63,"sold_individually":22,"weight":59,"dimensions":173,"shipping_required":64,"shipping_taxable":64,"shipping_class":59,"shipping_class_id":72,"reviews_allowed":64,"average_rating":73,"rating_count":72,"upsell_ids":174,"cross_sell_ids":175,"parent_id":72,"purchase_note":59,"categories":176,"brands":178,"tags":179,"images":180,"attributes":182,"default_attributes":185,"variations":187,"grouped_products":189,"menu_order":72,"price_html":190,"related_ids":191,"meta_data":195,"stock_status":223,"has_options":64,"post_password":59,"global_unique_id":59,"jetpack_sharing_enabled":64,"_links":224},"BPC-157\u002FTB-500 Blend","bpc-157-tb-500-blend","https:\u002F\u002Fapi.tlpeptides.com\u002Fproduct\u002Fbpc-157-tb-500-blend\u002F","2026-02-06T18:38:27","2026-05-18T18:07:08","TLP-BPC157-TB500-10MG","85",[],{"length":59,"width":59,"height":59},[],[],[177],{"id":78,"name":79,"slug":80},[],[],[181],{"id":85,"date_created":86,"date_created_gmt":86,"date_modified":87,"date_modified_gmt":87,"src":88,"name":89,"alt":59,"srcset":90,"sizes":91,"thumbnail":92},[183],{"id":72,"name":95,"slug":95,"position":72,"visible":64,"variation":64,"options":184},[97],[186],{"id":72,"name":95,"option":97},[188],3077,[],"\u003Cspan class=\"woocommerce-Price-amount amount\">\u003Cbdi>\u003Cspan class=\"woocommerce-Price-currencySymbol\">$\u003C\u002Fspan>85.00\u003C\u002Fbdi>\u003C\u002Fspan>",[105,50,192,193,194],2947,2835,3061,[196,198,200,202,204,206,208,211,214,216,218,221],{"id":197,"key":113,"value":114},10794,{"id":199,"key":113,"value":114},10813,{"id":201,"key":113,"value":114},10814,{"id":203,"key":113,"value":114},10815,{"id":205,"key":113,"value":114},10816,{"id":207,"key":113,"value":114},10817,{"id":209,"key":127,"value":210},10818,{"slider_visibility":129,"slider_type":70,"wooslider":130,"page_title_bar":131},{"id":212,"key":134,"value":213},10819,"120",{"id":215,"key":138,"value":114},10820,{"id":217,"key":141,"value":142},10821,{"id":219,"key":145,"value":220},10822,"9",{"id":222,"key":113,"value":114},10823,"outofstock",{"self":225,"collection":230},[226],{"href":227,"targetHints":228},"https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-json\u002Fwc\u002Fv3\u002Fproducts\u002F3075",{"allow":229},[156,157,158,159,160],[231],{"href":163},{"id":194,"name":233,"slug":234,"permalink":235,"date_created":236,"date_created_gmt":236,"date_modified":237,"date_modified_gmt":237,"type":56,"status":57,"featured":22,"catalog_visibility":58,"description":59,"short_description":60,"sku":238,"price":239,"regular_price":59,"sale_price":59,"date_on_sale_from":63,"date_on_sale_from_gmt":63,"date_on_sale_to":63,"date_on_sale_to_gmt":63,"on_sale":22,"purchasable":64,"total_sales":240,"virtual":22,"downloadable":22,"downloads":241,"download_limit":67,"download_expiry":67,"external_url":59,"button_text":59,"tax_status":68,"tax_class":59,"manage_stock":64,"stock_quantity":240,"backorders":70,"backorders_allowed":22,"backordered":22,"low_stock_amount":63,"sold_individually":22,"weight":59,"dimensions":242,"shipping_required":64,"shipping_taxable":64,"shipping_class":59,"shipping_class_id":72,"reviews_allowed":64,"average_rating":73,"rating_count":72,"upsell_ids":243,"cross_sell_ids":244,"parent_id":72,"purchase_note":59,"categories":245,"brands":247,"tags":248,"images":249,"attributes":251,"default_attributes":255,"variations":257,"grouped_products":259,"menu_order":72,"price_html":260,"related_ids":261,"meta_data":263,"stock_status":149,"has_options":64,"post_password":59,"global_unique_id":59,"jetpack_sharing_enabled":64,"_links":280},"CJC-1295","cjc-1295","https:\u002F\u002Fapi.tlpeptides.com\u002Fproduct\u002Fcjc-1295\u002F","2026-02-06T18:26:52","2026-05-18T18:07:06","TLP-CJC1295-10MG","100",5,[],{"length":59,"width":59,"height":59},[],[],[246],{"id":78,"name":79,"slug":80},[],[],[250],{"id":85,"date_created":86,"date_created_gmt":86,"date_modified":87,"date_modified_gmt":87,"src":88,"name":89,"alt":59,"srcset":90,"sizes":91,"thumbnail":92},[252],{"id":72,"name":95,"slug":95,"position":72,"visible":64,"variation":64,"options":253},[254,97],"5mg",[256],{"id":72,"name":95,"option":97},[258],3062,[],"\u003Cspan class=\"woocommerce-Price-amount amount\">\u003Cbdi>\u003Cspan class=\"woocommerce-Price-currencySymbol\">$\u003C\u002Fspan>100.00\u003C\u002Fbdi>\u003C\u002Fspan>",[262,192,109,193,50],2826,[264,266,269,272,274,276,278],{"id":265,"key":113,"value":114},10449,{"id":267,"key":127,"value":268},10469,{"slider_visibility":129,"slider_type":70,"wooslider":130,"page_title_bar":131},{"id":270,"key":134,"value":271},10470,"101",{"id":273,"key":138,"value":114},10471,{"id":275,"key":141,"value":142},10472,{"id":277,"key":145,"value":220},10473,{"id":279,"key":113,"value":114},10474,{"self":281,"collection":286},[282],{"href":283,"targetHints":284},"https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-json\u002Fwc\u002Fv3\u002Fproducts\u002F3061",{"allow":285},[156,157,158,159,160],[287],{"href":163},{"id":105,"name":289,"slug":290,"permalink":291,"date_created":292,"date_created_gmt":292,"date_modified":293,"date_modified_gmt":293,"type":56,"status":57,"featured":22,"catalog_visibility":58,"description":294,"short_description":60,"sku":295,"price":296,"regular_price":59,"sale_price":59,"date_on_sale_from":63,"date_on_sale_from_gmt":63,"date_on_sale_to":63,"date_on_sale_to_gmt":63,"on_sale":22,"purchasable":64,"total_sales":72,"virtual":22,"downloadable":22,"downloads":297,"download_limit":67,"download_expiry":67,"external_url":59,"button_text":59,"tax_status":68,"tax_class":59,"manage_stock":64,"stock_quantity":298,"backorders":70,"backorders_allowed":22,"backordered":22,"low_stock_amount":63,"sold_individually":22,"weight":59,"dimensions":299,"shipping_required":64,"shipping_taxable":64,"shipping_class":59,"shipping_class_id":72,"reviews_allowed":64,"average_rating":73,"rating_count":72,"upsell_ids":300,"cross_sell_ids":301,"parent_id":72,"purchase_note":59,"categories":302,"brands":304,"tags":305,"images":306,"attributes":308,"default_attributes":313,"variations":315,"grouped_products":317,"menu_order":72,"price_html":318,"related_ids":319,"meta_data":321,"stock_status":149,"has_options":64,"post_password":59,"global_unique_id":59,"jetpack_sharing_enabled":64,"_links":339},"GHK-Cu","ghk-cu","https:\u002F\u002Fapi.tlpeptides.com\u002Fproduct\u002Fghk-cu\u002F","2025-12-05T01:17:06","2026-05-18T18:07:05","\u003Ch2>GHK-Cu Peptide\u003C\u002Fh2>\n\u003Cp>GHK-Cu (glycyl-L-histidyl-L-lysine-copper(II)) is a naturally occurring copper-binding peptide complex found in human plasma, saliva, and urine. This tripeptide-copper complex has been extensively investigated for its potential roles in tissue repair, wound healing, skin regeneration, and anti-aging applications across various research models.\u003C\u002Fp>\n\u003Cp>GHK-Cu consists of three amino acids—glycine, histidine, and lysine—with a high affinity for copper ions (Cu2+). The peptide was first isolated from human plasma and identified as a growth-modulating factor. Research has demonstrated that GHK-Cu levels decline with age, decreasing from approximately 200 ng\u002FmL at age 20 to about 80 ng\u002FmL by age 60, prompting investigations into its potential therapeutic applications.(1)\u003C\u002Fp>\n\u003Ch2>Overview\u003C\u002Fh2>\n\u003Cp>GHK-Cu has been extensively investigated for its multifunctional biological activities, including stimulation of collagen and glycosaminoglycan synthesis, promotion of angiogenesis, modulation of metalloproteinase activity, and anti-inflammatory effects. Research indicates that the copper complex exhibits significantly greater biological activity compared to the peptide alone, suggesting that copper coordination is essential for many of its functions.(2)\u003C\u002Fp>\n\u003Cp>Studies have demonstrated that GHK-Cu influences gene expression patterns, affecting thousands of genes involved in tissue remodeling, antioxidant responses, and cellular signaling. The peptide-copper complex has been investigated for applications in dermatology, wound care, hair growth, and systemic anti-aging interventions.(3)\u003C\u002Fp>\n\u003Ch2>Chemical Makeup\u003C\u002Fh2>\n\u003Cp>\u003Cstrong>Molecular Formula:\u003C\u002Fstrong> C14H22N6O4Cu\u003Cbr \u002F>\n\u003Cstrong>Molecular Weight:\u003C\u002Fstrong> 401.91 g\u002Fmol (copper complex)\u003Cbr \u002F>\n\u003Cstrong>Sequence:\u003C\u002Fstrong> Gly-His-Lys-Cu2+ (H-GHK-Cu-OH)\u003Cbr \u002F>\n\u003Cstrong>Other Known Titles:\u003C\u002Fstrong> Copper peptide, Copper tripeptide-1, Growth-modulating peptide\u003C\u002Fp>\n\u003Ch2>Research and Clinical Studies\u003C\u002Fh2>\n\u003Ch3>GHK-Cu and Wound Healing\u003C\u002Fh3>\n\u003Cp>Research examining GHK-Cu in wound healing has demonstrated accelerated tissue repair across multiple experimental models. Studies indicated that GHK-Cu application appeared to increase the rate of wound closure, enhance granulation tissue formation, and improve the quality of healed tissue compared to control treatments.(4)\u003C\u002Fp>\n\u003Cp>Investigations into cellular mechanisms suggested that GHK-Cu may stimulate fibroblast proliferation and migration, processes critical for wound repair. Research demonstrated increased fibroblast activity and collagen deposition in wounds treated with GHK-Cu, potentially contributing to enhanced structural integrity of healing tissue.(5)\u003C\u002Fp>\n\u003Cp>Studies exploring angiogenesis in wound healing suggested that GHK-Cu may promote blood vessel formation in healing tissues. Research indicated increased vascular density and improved tissue perfusion in GHK-Cu-treated wounds, which may facilitate nutrient and oxygen delivery essential for optimal healing.(6)\u003C\u002Fp>\n\u003Ch3>GHK-Cu and Collagen Synthesis\u003C\u002Fh3>\n\u003Cp>Research investigating GHK-Cu's effects on collagen production has consistently demonstrated stimulatory effects. Studies in cultured fibroblasts indicated that GHK-Cu treatment appeared to increase collagen type I synthesis, the predominant collagen in skin and connective tissues.(7)\u003C\u002Fp>\n\u003Cp>Investigations examining glycosaminoglycan synthesis suggested that GHK-Cu may also enhance production of these extracellular matrix components. Research indicated increased synthesis of dermatan sulfate and other glycosaminoglycans, which contribute to tissue hydration and structural organization.(8)\u003C\u002Fp>\n\u003Cp>Studies exploring molecular mechanisms suggested that GHK-Cu may influence collagen synthesis through multiple pathways, including stimulation of transforming growth factor-beta (TGF-β) and modulation of gene expression patterns related to extracellular matrix production.(9)\u003C\u002Fp>\n\u003Ch3>GHK-Cu and Skin Regeneration\u003C\u002Fh3>\n\u003Cp>Research examining GHK-Cu in skin aging has demonstrated multiple beneficial effects on aged skin. Studies indicated that topical GHK-Cu application appeared to increase skin thickness, improve skin density, and enhance overall skin appearance in both animal models and human subjects.(10)\u003C\u002Fp>\n\u003Cp>Investigations into photoaging suggested that GHK-Cu may address ultraviolet radiation-induced skin damage. Research demonstrated improvements in fine lines, wrinkles, skin laxity, and pigmentation irregularities following GHK-Cu treatment in photoaged skin.(11)\u003C\u002Fp>\n\u003Cp>Studies exploring skin barrier function suggested that GHK-Cu may enhance epidermal barrier integrity. Research indicated improvements in transepidermal water loss measurements and increased expression of barrier-related proteins, potentially contributing to improved skin hydration and protection.(12)\u003C\u002Fp>\n\u003Ch3>GHK-Cu and Metalloproteinase Regulation\u003C\u002Fh3>\n\u003Cp>Research investigating GHK-Cu's effects on matrix metalloproteinases (MMPs) has revealed complex regulatory activities. Studies indicated that GHK-Cu may reduce excessive MMP activity in damaged or aged tissues while maintaining appropriate levels for normal tissue remodeling.(13)\u003C\u002Fp>\n\u003Cp>Investigations examining specific MMPs suggested that GHK-Cu may decrease MMP-1 (collagenase) and MMP-2 (gelatinase) activity in certain contexts. Research indicated that this modulation may prevent excessive collagen degradation while promoting appropriate extracellular matrix turnover.(14)\u003C\u002Fp>\n\u003Cp>Studies exploring tissue inhibitors of metalloproteinases (TIMPs) suggested that GHK-Cu may influence the MMP\u002FTIMP balance. Research demonstrated increased TIMP expression in some experimental models, potentially contributing to preservation of extracellular matrix integrity.(15)\u003C\u002Fp>\n\u003Ch3>GHK-Cu and Anti-Inflammatory Effects\u003C\u002Fh3>\n\u003Cp>Research examining GHK-Cu's inflammatory modulation has demonstrated anti-inflammatory properties across various models. Studies indicated that GHK-Cu treatment appeared to reduce pro-inflammatory cytokine production, including interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α).(16)\u003C\u002Fp>\n\u003Cp>Investigations into inflammatory signaling pathways suggested that GHK-Cu may inhibit nuclear factor kappa B (NF-κB) activation. Research indicated reduced NF-κB nuclear translocation and decreased expression of NF-κB-dependent inflammatory genes in cells treated with GHK-Cu.(17)\u003C\u002Fp>\n\u003Cp>Studies exploring oxidative stress suggested that GHK-Cu may exhibit antioxidant properties. Research demonstrated increased expression of antioxidant enzymes and reduced markers of oxidative damage in tissues treated with the peptide-copper complex.(18)\u003C\u002Fp>\n\u003Ch3>GHK-Cu and Gene Expression\u003C\u002Fh3>\n\u003Cp>Research investigating GHK-Cu's effects on gene expression has revealed extensive regulatory activities. Studies utilizing gene microarray analysis indicated that GHK-Cu treatment affected expression of over 30% of human genes, with particularly strong effects on genes involved in tissue remodeling and cellular responses to stress.(3)\u003C\u002Fp>\n\u003Cp>Investigations into specific gene categories suggested that GHK-Cu may upregulate genes involved in antioxidant responses, DNA repair, and protein folding while downregulating genes associated with inflammation, fibrosis, and oxidative damage. Research indicated that these expression patterns may contribute to tissue regeneration and anti-aging effects.(3)\u003C\u002Fp>\n\u003Cp>Studies examining epigenetic mechanisms suggested that GHK-Cu may influence chromatin remodeling and gene accessibility. Research indicated potential effects on histone modifications and DNA methylation patterns, though mechanisms require further investigation.(19)\u003C\u002Fp>\n\u003Ch3>GHK-Cu and Hair Growth\u003C\u002Fh3>\n\u003Cp>Research examining GHK-Cu in hair biology has suggested potential applications for hair loss conditions. Studies indicated that GHK-Cu treatment appeared to increase hair follicle size, prolong the anagen (growth) phase, and stimulate hair growth in some experimental models.(20)\u003C\u002Fp>\n\u003Cp>Investigations into mechanisms suggested that GHK-Cu may influence hair follicle stem cell activity and dermal papilla cell function. Research demonstrated increased proliferation of follicular cells and enhanced expression of growth factors associated with hair follicle cycling.(20)\u003C\u002Fp>\n\u003Ch3>GHK-Cu and Nervous System\u003C\u002Fh3>\n\u003Cp>Research investigating GHK-Cu in nervous tissue has explored potential neuroprotective and neuroregenerative effects. Studies indicated that GHK-Cu treatment appeared to support neurite outgrowth and protect neurons from various stress conditions in cell culture models.(2)\u003C\u002Fp>\n\u003Cp>Investigations into nerve regeneration suggested that GHK-Cu may promote peripheral nerve repair. Research in nerve injury models demonstrated improved functional recovery and enhanced nerve regeneration with GHK-Cu treatment, though mechanisms appeared complex and multifactorial.(2)\u003C\u002Fp>\n\u003Ch3>GHK-Cu Delivery and Formulation\u003C\u002Fh3>\n\u003Cp>Research investigating optimal delivery methods for GHK-Cu has explored various formulation strategies. Studies examining topical delivery indicated that appropriate vehicle selection, pH optimization, and penetration enhancement strategies may improve GHK-Cu efficacy in dermatological applications.(10)\u003C\u002Fp>\n\u003Cp>Investigations into stability considerations suggested that GHK-Cu formulations require careful attention to copper coordination and oxidation prevention. Research indicated that proper formulation techniques may preserve peptide-copper complex integrity and maintain biological activity during storage and application.(1)\u003C\u002Fp>\n\u003Cp>Studies exploring alternative delivery routes, including subcutaneous and systemic administration, have examined biodistribution and systemic effects. Research indicated that delivery route selection may influence the spectrum of biological effects and therapeutic applications.(2)\u003C\u002Fp>\n\u003Ch3>GHK-Cu Safety and Tolerability\u003C\u002Fh3>\n\u003Cp>Research investigating GHK-Cu's safety profile has generally indicated favorable tolerability in preclinical and clinical studies. Studies examining topical application reported minimal adverse reactions, with most investigations noting excellent skin tolerability across various concentrations and formulations.(10)\u003C\u002Fp>\n\u003Cp>Investigations into systemic effects following topical application suggested minimal systemic absorption due to the peptide's relatively large size and charged nature. Research indicated that GHK-Cu primarily exerts local effects when applied topically, contributing to its favorable safety profile.(11)\u003C\u002Fp>\n\u003Cp>Studies examining long-term use in dermatological applications have reported sustained benefits without evidence of tolerance development or cumulative toxicity. Research indicated that repeated GHK-Cu application maintained efficacy over extended treatment periods.(11)\u003C\u002Fp>\n\u003Ch2>Available for Research Purposes Only\u003C\u002Fh2>\n\u003Cp>GHK-Cu peptide complex is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.\u003C\u002Fp>\n\u003Ch2>References\u003C\u002Fh2>\n\u003Col>\n\u003Cli>Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987.\u003C\u002Fli>\n\u003Cli>Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-988.\u003C\u002Fli>\n\u003Cli>Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev. 2012;2012:324832.\u003C\u002Fli>\n\u003Cli>Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994;2(4):259-269.\u003C\u002Fli>\n\u003Cli>Pollard JD, Quan S, Kang T, Koch RJ. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Arch Facial Plast Surg. 2005;7(1):27-31.\u003C\u002Fli>\n\u003Cli>Siméon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;67(18):2257-2265.\u003C\u002Fli>\n\u003Cli>McCormack MC, Nowak KC, Koch RJ. The effect of copper tripeptide and tretinoin on growth factor production in a serum-free fibroblast model. Arch Facial Plast Surg. 2001;3(1):28-32.\u003C\u002Fli>\n\u003Cli>Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-346.\u003C\u002Fli>\n\u003Cli>Grether-Beck S, Felsner I, Brenden H, et al. Urea uptake enhances barrier function and antimicrobial defense in humans by regulating epidermal gene expression. J Invest Dermatol. 2012;132(6):1561-1572.\u003C\u002Fli>\n\u003Cli>Appa ZH, Barkovic S, Pickart L. Skin Regenerative and Anti-Cancer Actions of Copper Peptides. Cosmetics. 2018;5(2):29.\u003C\u002Fli>\n\u003Cli>Finkley MB, Appa Y, Bhandarkar S. Copper peptide and skin. Cosmeceuticals and Active Cosmetics. 2005:549-563.\u003C\u002Fli>\n\u003Cli>Wegrowski Y, Maquart FX, Borel JP. Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. Life Sci. 1992;51(13):1049-1056.\u003C\u002Fli>\n\u003Cli>Kang YA, Choi HR, Na JI, et al. Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Arch Dermatol Res. 2009;301(4):301-306.\u003C\u002Fli>\n\u003Cli>Siméon A, Monier F, Emonard H, et al. Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 1999;112(6):957-964.\u003C\u002Fli>\n\u003Cli>Lovejoy B, Cleasby A, Hassell AM, et al. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. Science. 1994;263(5145):375-377.\u003C\u002Fli>\n\u003Cli>Miller J, Djabali K, Chen T, et al. Atopy patch test reactions show augmented IL-16 expression and decreased keratinocyte cell differentiation. J Am Acad Dermatol. 2005;52(3 Pt 1):468-478.\u003C\u002Fli>\n\u003Cli>Choi HR, Kang YA, Ryoo SJ, Shin JW, Na JI, Huh CH, Park KC. Involvement of the p38 mitogen-activated protein kinase pathway in the induction of melanogenesis by alpha-melanocyte-stimulating hormone. Arch Dermatol Res. 2011;303(7):513-519.\u003C\u002Fli>\n\u003Cli>Park JR, Lee H, Kim SI, Yang SR. The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget. 2016;7(36):58405-58417.\u003C\u002Fli>\n\u003Cli>Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108.\u003C\u002Fli>\n\u003Cli>Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-839.\u003C\u002Fli>\n\u003C\u002Fol>\n","TLP-GHKCU-50MG","55",[],20,{"length":59,"width":59,"height":59},[],[],[303],{"id":78,"name":79,"slug":80},[],[],[307],{"id":85,"date_created":86,"date_created_gmt":86,"date_modified":87,"date_modified_gmt":87,"src":88,"name":89,"alt":59,"srcset":90,"sizes":91,"thumbnail":92},[309],{"id":72,"name":95,"slug":95,"position":72,"visible":64,"variation":64,"options":310},[311,312],"50mg","100mg",[314],{"id":72,"name":95,"option":311},[316],3060,[],"\u003Cspan class=\"woocommerce-Price-amount amount\">\u003Cbdi>\u003Cspan class=\"woocommerce-Price-currencySymbol\">$\u003C\u002Fspan>55.00\u003C\u002Fbdi>\u003C\u002Fspan>",[320,262,107,193,50],2836,[322,324,327,330,332,334,336],{"id":323,"key":113,"value":114},9898,{"id":325,"key":127,"value":326},9917,{"slider_visibility":129,"slider_type":70,"wooslider":130,"page_title_bar":131},{"id":328,"key":134,"value":329},9918,"67",{"id":331,"key":138,"value":114},9919,{"id":333,"key":141,"value":142},9920,{"id":335,"key":113,"value":114},9921,{"id":337,"key":145,"value":338},9922,"11",{"self":340,"collection":345},[341],{"href":342,"targetHints":343},"https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-json\u002Fwc\u002Fv3\u002Fproducts\u002F2954",{"allow":344},[156,157,158,159,160],[346],{"href":163},{"id":192,"name":348,"slug":349,"permalink":350,"date_created":351,"date_created_gmt":351,"date_modified":352,"date_modified_gmt":352,"type":56,"status":57,"featured":22,"catalog_visibility":58,"description":353,"short_description":60,"sku":354,"price":62,"regular_price":59,"sale_price":59,"date_on_sale_from":63,"date_on_sale_from_gmt":63,"date_on_sale_to":63,"date_on_sale_to_gmt":63,"on_sale":22,"purchasable":64,"total_sales":72,"virtual":22,"downloadable":22,"downloads":355,"download_limit":67,"download_expiry":67,"external_url":59,"button_text":59,"tax_status":68,"tax_class":59,"manage_stock":64,"stock_quantity":72,"backorders":70,"backorders_allowed":22,"backordered":22,"low_stock_amount":63,"sold_individually":22,"weight":59,"dimensions":356,"shipping_required":64,"shipping_taxable":64,"shipping_class":59,"shipping_class_id":72,"reviews_allowed":64,"average_rating":73,"rating_count":72,"upsell_ids":357,"cross_sell_ids":358,"parent_id":72,"purchase_note":59,"categories":359,"brands":361,"tags":362,"images":363,"attributes":365,"default_attributes":369,"variations":371,"grouped_products":373,"menu_order":72,"price_html":103,"related_ids":374,"meta_data":375,"stock_status":223,"has_options":64,"post_password":59,"global_unique_id":59,"jetpack_sharing_enabled":64,"_links":392},"NAD+","nad","https:\u002F\u002Fapi.tlpeptides.com\u002Fproduct\u002Fnad\u002F","2025-12-05T00:55:13","2026-05-18T18:07:07","\u003Ch2>Nicotinamide Adenine Dinucleotide (NAD+)\u003C\u002Fh2>\n\u003Cp>Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme found in all living cells that plays fundamental roles in cellular metabolism, energy production, DNA repair, and cellular signaling. The molecule exists in oxidized (NAD+) and reduced (NADH) forms, functioning as a critical electron carrier in redox reactions throughout cellular metabolism.\u003C\u002Fp>\n\u003Cp>NAD+ is a dinucleotide composed of two nucleotides joined through their phosphate groups. One nucleotide contains an adenine nucleobase and the other contains nicotinamide. The molecule participates in hundreds of enzymatic reactions and serves as a substrate for several enzyme families that regulate cellular function and longevity.(1)\u003C\u002Fp>\n\u003Ch2>Overview\u003C\u002Fh2>\n\u003Cp>NAD+ has been extensively investigated for its central role in cellular bioenergetics and its involvement in critical physiological processes. Research indicates that NAD+ functions as a coenzyme in oxidation-reduction reactions, particularly in glycolysis, the citric acid cycle, and oxidative phosphorylation. The molecule also serves as a substrate for NAD+-consuming enzymes including sirtuins, poly(ADP-ribose) polymerases (PARPs), and CD38.(2)\u003C\u002Fp>\n\u003Cp>Studies have demonstrated that NAD+ levels decline with aging across multiple tissues and organisms. This age-related decline has been associated with various metabolic and functional impairments, prompting extensive research into NAD+ supplementation and precursor molecules. Investigations have explored the potential of NAD+ restoration to influence healthspan, metabolic function, and age-related physiological decline.(3)\u003C\u002Fp>\n\u003Ch2>Chemical Makeup\u003C\u002Fh2>\n\u003Cp>Molecular Formula: C21H27N7O14P2\u003Cbr \u002F>\nMolecular Weight: 663.43 g\u002Fmol\u003Cbr \u002F>\nOther Known Titles: Coenzyme I, DPN, Diphosphopyridine nucleotide, β-Nicotinamide adenine dinucleotide\u003C\u002Fp>\n\u003Ch2>Research and Clinical Studies\u003C\u002Fh2>\n\u003Ch3>NAD+ and Cellular Bioenergetics\u003C\u002Fh3>\n\u003Cp>Research examining NAD+ in cellular energy metabolism has demonstrated its essential role as an electron acceptor in catabolic processes. Studies indicate that NAD+ accepts electrons during glycolysis, beta-oxidation, and the citric acid cycle, becoming reduced to NADH. The NADH subsequently donates electrons to the electron transport chain, facilitating ATP production through oxidative phosphorylation.(4)\u003C\u002Fp>\n\u003Cp>Studies examining NAD+\u002FNADH ratios suggested that this balance serves as a critical indicator of cellular metabolic state. Research indicated that alterations in NAD+\u002FNADH ratios may influence the activity of NAD+-dependent enzymes and impact cellular redox status, potentially affecting metabolic flux through various pathways.(4)\u003C\u002Fp>\n\u003Ch3>NAD+ and Sirtuin Activation\u003C\u002Fh3>\n\u003Cp>Research investigating sirtuin enzymes has demonstrated their dependence on NAD+ as a substrate for their deacetylase activity. Studies indicated that sirtuins remove acetyl groups from target proteins while consuming NAD+ and producing nicotinamide and O-acetyl-ADP-ribose as byproducts.(5)\u003C\u002Fp>\n\u003Cp>Investigations examining SIRT1, the most extensively studied mammalian sirtuin, suggested its involvement in metabolic regulation, stress resistance, and longevity pathways. Research indicated that SIRT1 may deacetylate numerous substrates including PGC-1α, FOXO transcription factors, and p53, potentially influencing mitochondrial biogenesis, oxidative stress responses, and inflammatory signaling.(6)\u003C\u002Fp>\n\u003Cp>Studies exploring mitochondrial sirtuins suggested that SIRT3, localized primarily in mitochondria, may regulate mitochondrial protein acetylation and influence oxidative metabolism. Investigations into the relationship between NAD+ availability and sirtuin activity suggested that NAD+ levels may modulate sirtuin function.(7)\u003C\u002Fp>\n\u003Ch3>NAD+ Decline with Aging\u003C\u002Fh3>\n\u003Cp>Research investigating age-related changes in NAD+ levels has consistently demonstrated declines across multiple tissues and model organisms. Studies in rodents indicated that NAD+ concentrations in liver, skeletal muscle, adipose tissue, and brain tissue decreased significantly with advancing age, with some tissues showing reductions exceeding 50% between young and old animals.(8)\u003C\u002Fp>\n\u003Cp>Studies exploring mechanisms underlying NAD+ decline suggested multiple contributing factors. Research indicated that increased expression and activity of CD38, an NAD+-consuming enzyme, may contribute to age-related NAD+ depletion. Additional investigations suggested that decreased expression of NAD+ biosynthetic enzymes and increased NAD+ consumption by PARPs responding to accumulated DNA damage may also contribute.(9)\u003C\u002Fp>\n\u003Cp>Research examining consequences of age-related NAD+ decline suggested associations with mitochondrial dysfunction, reduced sirtuin activity, impaired cellular stress responses, and metabolic alterations. Studies indicated that these changes may contribute to various age-associated pathological conditions.(8)\u003C\u002Fp>\n\u003Ch3>NAD+ Precursors and Biosynthetic Pathways\u003C\u002Fh3>\n\u003Cp>Research has identified multiple pathways for NAD+ biosynthesis, utilizing different precursor molecules. Investigations into salvage pathways, which recycle NAD+ breakdown products, suggested these routes represent the primary mechanism for NAD+ maintenance in most tissues. Research indicated that nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) function as key intermediates, with specific enzymes catalyzing their conversion to NAD+.(10)\u003C\u002Fp>\n\u003Cp>Studies examining nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the salvage pathway from nicotinamide, suggested its critical role in maintaining NAD+ levels. Research indicated that NAMPT expression and activity may influence cellular NAD+ concentrations and downstream NAD+-dependent processes.(11)\u003C\u002Fp>\n\u003Cp>Investigations comparing different NAD+ precursors suggested varying efficacy in raising tissue NAD+ levels. Research indicated that NMN and NR, which bypass NAMPT in the biosynthetic pathway, may effectively increase NAD+ concentrations when administered exogenously.(3)\u003C\u002Fp>\n\u003Ch3>NAD+ and Mitochondrial Function\u003C\u002Fh3>\n\u003Cp>Research examining mitochondrial NAD+ has suggested its critical importance for oxidative metabolism. Studies indicated that mitochondrial NAD+ levels may influence the activity of NAD+-dependent dehydrogenases in the citric acid cycle and beta-oxidation pathways, potentially affecting mitochondrial ATP production capacity.(12)\u003C\u002Fp>\n\u003Cp>Studies examining NAD+ supplementation effects on mitochondrial function reported improvements in aged rodents. Research suggested that NAD+ precursor administration appeared to improve mitochondrial respiration capacity, increase mitochondrial protein content, and enhance oxidative metabolism in some tissues.(8)\u003C\u002Fp>\n\u003Ch3>NAD+ and Cardiovascular Function\u003C\u002Fh3>\n\u003Cp>Research examining NAD+ in cardiovascular tissues has suggested its involvement in cardiac metabolism and stress responses. Studies indicated that cardiac NAD+ levels may influence mitochondrial function and energy production in the metabolically demanding myocardium.(13)\u003C\u002Fp>\n\u003Cp>Studies examining vascular function suggested that NAD+-dependent pathways may influence endothelial cell function and vascular tone. Research indicated that SIRT1 activation in endothelial cells appeared to promote nitric oxide production and reduce inflammatory responses, potentially contributing to vascular health.(14)\u003C\u002Fp>\n\u003Cp>Investigations into age-related vascular dysfunction suggested that declining NAD+ levels might contribute to endothelial impairment. Research indicated that NAD+ precursor supplementation appeared to improve endothelial function and reduce arterial stiffness in aged animals.(15)\u003C\u002Fp>\n\u003Ch3>NAD+ and Skeletal Muscle Function\u003C\u002Fh3>\n\u003Cp>Research investigating skeletal muscle NAD+ has demonstrated its importance for muscle metabolism and function. Studies indicated that NAD+ levels in skeletal muscle decline with aging and may be reduced in various muscle pathologies.(16)\u003C\u002Fp>\n\u003Cp>Studies exploring NAD+ supplementation effects on muscle function reported improvements in aged animals. Research suggested that NAD+ precursor administration appeared to improve muscle mitochondrial function, increase muscle mass, and enhance exercise capacity in some experimental protocols. Investigations into muscle regeneration suggested that NAD+-dependent pathways may influence satellite cell function and muscle repair, with potential benefits for muscle stem cell activation.(17)\u003C\u002Fp>\n\u003Ch3>NAD+ and Neurodegenerative Processes\u003C\u002Fh3>\n\u003Cp>Research investigating NAD+ in neuronal function has suggested its importance for neuronal energy metabolism and stress resistance. Studies indicated that neurons, with their high energy demands and limited regenerative capacity, may be particularly vulnerable to NAD+ depletion.(18)\u003C\u002Fp>\n\u003Cp>Investigations into neurodegenerative disease models suggested potential protective effects of NAD+ restoration. Research in animal models of Alzheimer's disease indicated that NAD+ precursor supplementation appeared to reduce pathology, improve mitochondrial function, and enhance cognitive performance in some experimental paradigms.(18)\u003C\u002Fp>\n\u003Ch3>NAD+ Supplementation Strategies\u003C\u002Fh3>\n\u003Cp>Research investigating different approaches to increase NAD+ levels has examined various precursor molecules and administration routes. Studies comparing oral supplementation with NMN, NR, nicotinamide, and nicotinic acid suggested varying efficacy in raising tissue NAD+ concentrations.(19)\u003C\u002Fp>\n\u003Cp>Investigations into NMN supplementation indicated that oral administration appeared to increase NAD+ levels in multiple tissues in rodent studies. Research suggested that NMN may be absorbed and subsequently converted to NAD+ through tissue-specific pathways.(20)\u003C\u002Fp>\n\u003Cp>Studies examining NR supplementation suggested its ability to increase tissue NAD+ levels following oral administration. Research indicated that NR may utilize specific transporters for cellular uptake and is subsequently phosphorylated to form NMN, which is then converted to NAD+.(10)\u003C\u002Fp>\n\u003Cp>Investigations into human supplementation studies with NAD+ precursors have reported varying outcomes. Research indicated that NR and NMN supplementation appeared to increase blood NAD+ metabolite levels in humans, though tissue-specific effects and functional outcomes have shown variable results across studies.(19)\u003C\u002Fp>\n\u003Cp>Available for Research Purposes Only\u003C\u002Fp>\n\u003Cp>NAD+ and its precursors are available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.\u003C\u002Fp>\n\u003Ch2>References\u003C\u002Fh2>\n\u003Cp>1. Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. Trends Biochem Sci. 2007;32(1):12-19.\u003C\u002Fp>\n\u003Cp>2. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213.\u003C\u002Fp>\n\u003Cp>3. Yoshino J, Baur JA, Imai SI. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018;27(3):513-528.\u003C\u002Fp>\n\u003Cp>4. Ying W. NAD+\u002FNADH and NADP+\u002FNADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal. 2008;10(2):179-206.\u003C\u002Fp>\n\u003Cp>5. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-471.\u003C\u002Fp>\n\u003Cp>6. Chang HC, Guarente L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab. 2014;25(3):138-145.\u003C\u002Fp>\n\u003Cp>7. Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol. 2010;5:253-295.\u003C\u002Fp>\n\u003Cp>8. Gomes AP, Price NL, Ling AJ, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624-1638.\u003C\u002Fp>\n\u003Cp>9. Camacho-Pereira J, Tarragó MG, Chini CC, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23(6):1127-1139.\u003C\u002Fp>\n\u003Cp>10. Bieganowski P, Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell. 2004;117(4):495-502.\u003C\u002Fp>\n\u003Cp>11. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279(49):50754-50763.\u003C\u002Fp>\n\u003Cp>12. Yang Y, Sauve AA. NAD+ metabolism: Bioenergetics, signaling and manipulation for therapy. Biochim Biophys Acta. 2016;1864(12):1787-1800.\u003C\u002Fp>\n\u003Cp>13. Diguet N, Trammell SAJ, Tannous C, et al. Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy. Circulation. 2018;137(21):2256-2273.\u003C\u002Fp>\n\u003Cp>14. Mattagajasingh I, Kim CS, Naqvi A, et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 2007;104(37):14855-14860.\u003C\u002Fp>\n\u003Cp>15. de Picciotto NE, Gano LB, Johnson LC, et al. Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. Aging Cell. 2016;15(3):522-530.\u003C\u002Fp>\n\u003Cp>16. Frederick DW, Loro E, Liu L, et al. Loss of NAD Homeostasis Leads to Progressive and Reversible Degeneration of Skeletal Muscle. Cell Metab. 2016;24(2):269-282.\u003C\u002Fp>\n\u003Cp>17. Zhang H, Ryu D, Wu Y, et al. NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science. 2016;352(6292):1436-1443.\u003C\u002Fp>\n\u003Cp>18. Long AN, Owens K, Schlappal AE, Kristian T, Fishman PS, Schuh RA. Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer's disease-relevant murine model. BMC Neurol. 2015;15:19.\u003C\u002Fp>\n\u003Cp>19. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286.\u003C\u002Fp>\n\u003Cp>20. Mills KF, Yoshida S, Stein LR, et al. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metab. 2016;24(6):795-806.\u003C\u002Fp>\n","TLP-NAD-500MG",[],{"length":59,"width":59,"height":59},[],[],[360],{"id":78,"name":79,"slug":80},[],[],[364],{"id":85,"date_created":86,"date_created_gmt":86,"date_modified":87,"date_modified_gmt":87,"src":88,"name":89,"alt":59,"srcset":90,"sizes":91,"thumbnail":92},[366],{"id":72,"name":95,"slug":95,"position":72,"visible":64,"variation":64,"options":367},[368],"500mg",[370],{"id":72,"name":95,"option":368},[372],2949,[],[262,194,193,107,109],[376,378,381,384,386,388,390],{"id":377,"key":113,"value":114},9759,{"id":379,"key":127,"value":380},9779,{"slider_visibility":129,"slider_type":70,"wooslider":130,"page_title_bar":131},{"id":382,"key":134,"value":383},9780,"54",{"id":385,"key":138,"value":114},9781,{"id":387,"key":141,"value":142},9782,{"id":389,"key":145,"value":338},9783,{"id":391,"key":113,"value":114},9784,{"self":393,"collection":398},[394],{"href":395,"targetHints":396},"https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-json\u002Fwc\u002Fv3\u002Fproducts\u002F2947",{"allow":397},[156,157,158,159,160],[399],{"href":163},{"id":108,"name":401,"slug":402,"permalink":403,"date_created":404,"date_created_gmt":404,"date_modified":405,"date_modified_gmt":405,"type":406,"status":57,"featured":22,"catalog_visibility":58,"description":59,"short_description":407,"sku":408,"price":409,"regular_price":409,"sale_price":59,"date_on_sale_from":63,"date_on_sale_from_gmt":63,"date_on_sale_to":63,"date_on_sale_to_gmt":63,"on_sale":22,"purchasable":64,"total_sales":410,"virtual":22,"downloadable":22,"downloads":411,"download_limit":67,"download_expiry":67,"external_url":59,"button_text":59,"tax_status":68,"tax_class":59,"manage_stock":64,"stock_quantity":412,"backorders":70,"backorders_allowed":22,"backordered":22,"low_stock_amount":63,"sold_individually":22,"weight":59,"dimensions":413,"shipping_required":64,"shipping_taxable":64,"shipping_class":59,"shipping_class_id":72,"reviews_allowed":64,"average_rating":73,"rating_count":72,"upsell_ids":414,"cross_sell_ids":415,"parent_id":72,"purchase_note":59,"categories":416,"brands":418,"tags":419,"images":424,"attributes":426,"default_attributes":430,"variations":431,"grouped_products":432,"menu_order":72,"price_html":433,"related_ids":434,"meta_data":435,"stock_status":149,"has_options":22,"post_password":59,"global_unique_id":59,"jetpack_sharing_enabled":64,"_links":450},"Bacteriostatic Water","bacteriostatic-water","https:\u002F\u002Fapi.tlpeptides.com\u002Fproduct\u002Fbacteriostatic-water\u002F","2025-12-04T20:17:46","2026-05-18T18:57:30","simple","\u003Ch3>\u003Cstrong data-start=\"316\" data-end=\"347\">Brand Name: \u003C\u002Fstrong>Generic\u003C\u002Fh3>\n\u003Ch3>Trusted by researchers for reliability and stability.\u003C\u002Fh3>\n\u003Cp>For researchers who are on the move or only need water occasionally, our \u003Cstrong>Reconstitution Solution\u003C\u002Fstrong> is the perfect option.\u003C\u002Fp>\n\u003Cp>\u003Cstrong>Why it’s ideal:\u003C\u002Fstrong>\u003C\u002Fp>\n\u003Cul>\n\u003Cli data-start=\"405\" data-end=\"448\">\n\u003Cp data-start=\"407\" data-end=\"448\">Formulated with \u003Cstrong data-start=\"423\" data-end=\"446\">0.9% benzyl alcohol\u003C\u002Fstrong>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli data-start=\"449\" data-end=\"495\">\n\u003Cp data-start=\"451\" data-end=\"495\">Securely sealed to help maintain stability\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli data-start=\"496\" data-end=\"547\">\n\u003Cp data-start=\"498\" data-end=\"547\">Convenient bulk pack for ongoing research needs\u003C\u002Fp>\n\u003C\u002Fli>\n\u003Cli data-start=\"548\" data-end=\"605\">\n\u003Cp data-start=\"550\" data-end=\"605\">Intended strictly for \u003Cstrong data-start=\"572\" data-end=\"603\">research and laboratory use\u003C\u002Fstrong>\u003C\u002Fp>\n\u003C\u002Fli>\n\u003C\u002Ful>\n","TLP-BACWTR-3ML","12",2,[],19,{"length":59,"width":59,"height":59},[],[],[417],{"id":78,"name":79,"slug":80},[],[420],{"id":421,"name":422,"slug":423},75,"Reconstitution Solution","reconstitution-solution",[425],{"id":85,"date_created":86,"date_created_gmt":86,"date_modified":87,"date_modified_gmt":87,"src":88,"name":89,"alt":59,"srcset":90,"sizes":91,"thumbnail":92},[427],{"id":72,"name":95,"slug":95,"position":72,"visible":64,"variation":22,"options":428},[429],"10ml",[],[],[],"\u003Cspan class=\"woocommerce-Price-amount amount\">\u003Cbdi>\u003Cspan class=\"woocommerce-Price-currencySymbol\">$\u003C\u002Fspan>12.00\u003C\u002Fbdi>\u003C\u002Fspan>",[105,194,193,192,50],[436,439,442,444,446,448],{"id":437,"key":127,"value":438},9515,{"slider_visibility":129,"slider_type":70,"wooslider":130,"page_title_bar":131},{"id":440,"key":134,"value":441},9517,"81",{"id":443,"key":138,"value":114},9518,{"id":445,"key":141,"value":142},9519,{"id":447,"key":113,"value":114},9533,{"id":449,"key":145,"value":146},9535,{"self":451,"collection":456},[452],{"href":453,"targetHints":454},"https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-json\u002Fwc\u002Fv3\u002Fproducts\u002F2926",{"allow":455},[156,157,158,159,160],[457],{"href":163},{"id":320,"name":459,"slug":460,"permalink":461,"date_created":462,"date_created_gmt":462,"date_modified":293,"date_modified_gmt":293,"type":56,"status":57,"featured":22,"catalog_visibility":58,"description":463,"short_description":60,"sku":464,"price":465,"regular_price":59,"sale_price":59,"date_on_sale_from":63,"date_on_sale_from_gmt":63,"date_on_sale_to":63,"date_on_sale_to_gmt":63,"on_sale":22,"purchasable":64,"total_sales":72,"virtual":22,"downloadable":22,"downloads":466,"download_limit":67,"download_expiry":67,"external_url":59,"button_text":59,"tax_status":68,"tax_class":59,"manage_stock":64,"stock_quantity":467,"backorders":70,"backorders_allowed":22,"backordered":22,"low_stock_amount":63,"sold_individually":22,"weight":59,"dimensions":468,"shipping_required":64,"shipping_taxable":64,"shipping_class":59,"shipping_class_id":72,"reviews_allowed":64,"average_rating":73,"rating_count":72,"upsell_ids":469,"cross_sell_ids":470,"parent_id":72,"purchase_note":59,"categories":471,"brands":473,"tags":474,"images":475,"attributes":485,"default_attributes":489,"variations":491,"grouped_products":493,"menu_order":72,"price_html":494,"related_ids":495,"meta_data":496,"stock_status":149,"has_options":64,"post_password":59,"global_unique_id":59,"jetpack_sharing_enabled":64,"_links":511},"Klow","klow","https:\u002F\u002Fapi.tlpeptides.com\u002Fproduct\u002Fklow\u002F","2025-12-02T04:47:07","\u003Ch2>KPV Tripeptide\u003C\u002Fh2>\n\u003Cp>KPV (Lys-Pro-Val) is a naturally occurring tripeptide derived from the C-terminal sequence of the anti-inflammatory hormone alpha-melanocyte stimulating hormone (α-MSH). This bioactive peptide has been investigated for its potential anti-inflammatory and immunomodulatory properties across various research models and tissue systems.\u003C\u002Fp>\n\u003Cp>KPV represents the smallest active fragment of α-MSH that retains anti-inflammatory activity. The tripeptide consists of three amino acids—lysine, proline, and valine—arranged in a specific sequence that appears critical for its biological activity. Research has explored KPV's potential mechanisms of action and therapeutic applications in inflammatory conditions.(1)\u003C\u002Fp>\n\u003Ch2>Overview\u003C\u002Fh2>\n\u003Cp>KPV has been extensively investigated for its anti-inflammatory properties independent of melanocortin receptor activation. Research indicates that KPV may exert its effects through multiple mechanisms, including modulation of inflammatory signaling pathways, inhibition of pro-inflammatory transcription factors, and direct effects on immune cell function.(2)\u003C\u002Fp>\n\u003Cp>Studies have demonstrated that KPV exhibits anti-inflammatory activity in various experimental models, including inflammatory bowel disease, dermatological conditions, and other inflammatory disorders. The peptide has been investigated for both systemic and topical applications, with research exploring optimal delivery methods and formulations.(3)\u003C\u002Fp>\n\u003Ch2>Chemical Makeup\u003C\u002Fh2>\n\u003Cp>Molecular Formula: C16H30N4O4\u003Cbr \u002F>\nMolecular Weight: 342.44 g\u002Fmol\u003Cbr \u002F>\nSequence: Lys-Pro-Val (H-KPV-OH)\u003Cbr \u002F>\nOther Known Titles: α-MSH(11-13), Melanocortin tripeptide\u003C\u002Fp>\n\u003Ch2>Research and Clinical Studies\u003C\u002Fh2>\n\u003Ch3>KPV and Anti-Inflammatory Mechanisms\u003C\u002Fh3>\n\u003Cp>Research examining KPV's anti-inflammatory mechanisms has suggested multiple pathways of action. Studies indicated that KPV may inhibit nuclear factor kappa B (NF-κB) translocation, a critical transcription factor involved in pro-inflammatory gene expression. Investigations demonstrated that KPV appeared to prevent NF-κB nuclear entry in activated immune cells, potentially reducing the expression of inflammatory cytokines.(4)\u003C\u002Fp>\n\u003Cp>Studies exploring intracellular mechanisms suggested that KPV may enter cells and exert direct intracellular effects. Research indicated that the peptide's anti-inflammatory activity may not depend entirely on cell surface receptor activation, distinguishing it from the parent hormone α-MSH, which primarily acts through melanocortin receptors.(5)\u003C\u002Fp>\n\u003Cp>Investigations into inflammatory mediator production suggested that KPV may reduce levels of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6). Research demonstrated dose-dependent reductions in these inflammatory markers across various cell types and experimental models.(6)\u003C\u002Fp>\n\u003Ch3>KPV and Inflammatory Bowel Disease\u003C\u002Fh3>\n\u003Cp>Research investigating KPV in inflammatory bowel disease (IBD) models has demonstrated potential therapeutic effects. Studies utilizing experimental colitis models indicated that KPV administration appeared to reduce intestinal inflammation, decrease disease severity scores, and improve histological outcomes.(7)\u003C\u002Fp>\n\u003Cp>Investigations examining oral and local administration routes suggested that KPV may exert beneficial effects on intestinal inflammation when delivered directly to affected tissues. Research indicated improvements in colonic inflammation markers, reduced immune cell infiltration, and preservation of intestinal barrier integrity in some experimental protocols.(8)\u003C\u002Fp>\n\u003Cp>Studies exploring KPV's effects on intestinal epithelial cells suggested potential protective mechanisms. Research indicated that the peptide may reduce epithelial cell apoptosis, enhance barrier function, and modulate tight junction protein expression, potentially contributing to improved intestinal homeostasis.(9)\u003C\u002Fp>\n\u003Ch3>KPV and Dermatological Applications\u003C\u002Fh3>\n\u003Cp>Research examining KPV in dermatological conditions has explored its potential for treating inflammatory skin disorders. Studies investigating contact dermatitis models indicated that topical KPV application appeared to reduce skin inflammation, decrease edema formation, and improve clinical inflammation scores.(10)\u003C\u002Fp>\n\u003Cp>Investigations into atopic dermatitis suggested that KPV may influence immune responses in skin tissue. Research demonstrated reductions in inflammatory cell infiltration, decreased expression of inflammatory markers, and improvements in skin barrier function parameters in some experimental models.(11)\u003C\u002Fp>\n\u003Cp>Studies exploring wound healing suggested that KPV may influence tissue repair processes. Research indicated potential effects on inflammatory phase regulation, with some investigations suggesting improved healing outcomes when KPV was incorporated into wound treatment protocols.(12)\u003C\u002Fp>\n\u003Ch3>KPV and Immune Cell Modulation\u003C\u002Fh3>\n\u003Cp>Research investigating KPV's effects on specific immune cell populations has demonstrated various immunomodulatory activities. Studies examining macrophages, key mediators of inflammatory responses, indicated that KPV appeared to shift macrophage polarization from pro-inflammatory M1 phenotypes toward anti-inflammatory M2 phenotypes.(13)\u003C\u002Fp>\n\u003Cp>Investigations into neutrophil function suggested that KPV may modulate neutrophil activation and migration. Research indicated potential effects on neutrophil chemotaxis and inflammatory mediator release, which may contribute to reduced tissue inflammation in various experimental models.(14)\u003C\u002Fp>\n\u003Cp>Studies exploring T cell responses suggested that KPV may influence lymphocyte activation and cytokine production. Research indicated potential modulatory effects on T helper cell differentiation and effector functions, though mechanisms appeared complex and context-dependent.(15)\u003C\u002Fp>\n\u003Ch3>KPV and Oxidative Stress\u003C\u002Fh3>\n\u003Cp>Research examining KPV's relationship with oxidative stress has suggested potential antioxidant properties. Studies indicated that KPV administration appeared to reduce markers of oxidative damage in some inflammatory models, including decreased lipid peroxidation and improved antioxidant enzyme activity.(16)\u003C\u002Fp>\n\u003Cp>Investigations into reactive oxygen species (ROS) production suggested that KPV may influence cellular redox balance. Research demonstrated reduced ROS generation in activated immune cells treated with KPV, potentially contributing to its anti-inflammatory effects through oxidative stress reduction.(17)\u003C\u002Fp>\n\u003Ch3>KPV Delivery and Formulation\u003C\u002Fh3>\n\u003Cp>Research investigating optimal delivery methods for KPV has explored various formulation strategies. Studies examining topical delivery indicated that appropriate vehicle selection and penetration enhancers may improve KPV's effectiveness in dermatological applications.(10)\u003C\u002Fp>\n\u003Cp>Investigations into oral delivery for intestinal applications suggested challenges related to peptide stability and absorption. Research explored protective formulations and targeted delivery systems designed to enhance KPV stability in the gastrointestinal environment and improve local bioavailability at sites of intestinal inflammation.(8)\u003C\u002Fp>\n\u003Cp>Studies examining nanoparticle and liposomal formulations suggested potential advantages for KPV delivery. Research indicated that encapsulation strategies may protect the peptide from degradation, enhance cellular uptake, and improve therapeutic efficacy in some experimental protocols.(18)\u003C\u002Fp>\n\u003Ch3>KPV and Melanocortin Receptor Independence\u003C\u002Fh3>\n\u003Cp>Research distinguishing KPV's mechanisms from melanocortin receptor-dependent pathways has provided important mechanistic insights. Studies utilizing melanocortin receptor antagonists indicated that KPV retained anti-inflammatory activity even when melanocortin receptors were blocked, suggesting receptor-independent mechanisms.(5)\u003C\u002Fp>\n\u003Cp>Investigations comparing KPV with full-length α-MSH demonstrated similar anti-inflammatory potency despite KPV's lack of melanocortin receptor binding affinity. Research suggested that KPV's ability to enter cells and act intracellularly may account for its melanocortin receptor-independent effects.(4)\u003C\u002Fp>\n\u003Ch3>KPV Structure-Activity Relationships\u003C\u002Fh3>\n\u003Cp>Research examining structural requirements for KPV's biological activity has investigated amino acid sequence importance and potential modifications. Studies exploring sequence variations indicated that the specific Lys-Pro-Val arrangement appeared critical for optimal anti-inflammatory activity, with altered sequences showing reduced potency.(1)\u003C\u002Fp>\n\u003Cp>Investigations into peptide modifications aimed at improving stability and bioavailability have explored various chemical alterations. Research examined D-amino acid substitutions, N-terminal modifications, and C-terminal amidation, with varying effects on peptide stability and biological activity.(19)\u003C\u002Fp>\n\u003Ch3>KPV Safety and Tolerability\u003C\u002Fh3>\n\u003Cp>Research investigating KPV's safety profile in preclinical models has generally indicated favorable tolerability. Studies examining acute and subchronic administration reported minimal adverse effects across various dose ranges and administration routes.(3)\u003C\u002Fp>\n\u003Cp>Investigations into potential systemic effects suggested that KPV, particularly when administered topically or locally, exhibited minimal systemic absorption and associated effects. Research indicated that the peptide's small size and specific delivery to target tissues may contribute to its favorable safety profile in experimental models.(20)\u003C\u002Fp>\n\u003Cp>Available for Research Purposes Only\u003C\u002Fp>\n\u003Cp>KPV tripeptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.\u003C\u002Fp>\n\u003Ch2>References\u003C\u002Fh2>\n\u003Cp>1. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602.\u003C\u002Fp>\n\u003Cp>2. Colombo G, Gatti S, Sordi A, et al. Production and effects of α-melanocyte-stimulating hormone during acute lung injury. Shock. 2007;27(3):326-333.\u003C\u002Fp>\n\u003Cp>3. Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. 1989;3(11):2282-2284.\u003C\u002Fp>\n\u003Cp>4. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331.\u003C\u002Fp>\n\u003Cp>5. Getting SJ, Riffo-Vasquez Y, Pitchford S, et al. A role for MC3R in modulating lung inflammation. Pulm Pharmacol Ther. 2008;21(6):866-873.\u003C\u002Fp>\n\u003Cp>6. Galimberti D, Fenoglio C, Lovati C, et al. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer's disease. Neurobiol Aging. 2006;27(12):1763-1768.\u003C\u002Fp>\n\u003Cp>7. Maaser C, Kannengiesser K, Specht C, et al. Crucial role of the melanocortin receptor MC1R in experimental colitis. Gut. 2006;55(10):1415-1422.\u003C\u002Fp>\n\u003Cp>8. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.\u003C\u002Fp>\n\u003Cp>9. Demers A, McNicoll N, Febbraio M, et al. Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochem J. 2004;382(Pt 2):417-424.\u003C\u002Fp>\n\u003Cp>10. Böhm M, Apel M, Schiller M, et al. Effect of topical application of the melanocortin peptide [Nle4, D-Phe7]-alpha-MSH on experimentally-induced immediate and delayed type hypersensitivity in skin. Exp Dermatol. 2006;15(7):551-558.\u003C\u002Fp>\n\u003Cp>11. Raap U, Brzoska T, Sohl S, et al. Alpha-melanocyte-stimulating hormone inhibits allergic airway inflammation. J Immunol. 2003;171(1):353-359.\u003C\u002Fp>\n\u003Cp>12. Kapas S, Cammas FM, Hinson JP, Clark AJ. Agonist and receptor binding properties of adrenomedullin 22-52, the NH2-terminal truncating analog of human adrenomedullin. Endocrinology. 1996;137(6):2456-2461.\u003C\u002Fp>\n\u003Cp>13. Si J, Ge Y, Zhuang S, Wang LJ, Chen S, Gong R. Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms. Kidney Int. 2013;83(4):635-646.\u003C\u002Fp>\n\u003Cp>14. Luger TA, Scholzen TE, Brzoska T, Böhm M. New insights into the functions of alpha-MSH and related peptides in the immune system. Ann N Y Acad Sci. 2003;994:133-140.\u003C\u002Fp>\n\u003Cp>15. Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev. 2004;56(1):1-29.\u003C\u002Fp>\n\u003Cp>16. Ichiyama T, Sakai T, Catania A, Barsh GS, Furukawa S, Lipton JM. Systemically administered alpha-melanocyte-stimulating peptides inhibit NF-kappaB activation in experimental brain inflammation. Brain Res. 1999;836(1-2):31-37.\u003C\u002Fp>\n\u003Cp>17. Delgado R, Carlin A, Airaghi L, et al. Melanocortin peptides inhibit production of proinflammatory cytokines and nitric oxide by activated microglia. J Leukoc Biol. 1998;63(6):740-745.\u003C\u002Fp>\n\u003Cp>18. Hartmeyer M, Scholzen T, Becher E, Bhardwaj RS, Schwarz T, Luger TA. Human dermal microvascular endothelial cells express the melanocortin receptor type 1 and produce increased levels of IL-8 upon stimulation with alpha-melanocyte-stimulating hormone. J Immunol. 1997;159(4):1930-1937.\u003C\u002Fp>\n\u003Cp>19. Taherzadeh S, Sharma S, Chhajlani V, Gantz I, Rajora N, Demitri MT, Kelly L, Zhao H, Ichiyama T, Catania A, Lipton JM. alpha-MSH and its receptors in regulation of tumor necrosis factor-alpha production by human monocyte\u002Fmacrophages. Am J Physiol. 1999;276(5):R1289-R1294.\u003C\u002Fp>\n\u003Cp>20. Holloway PM, Durrenberger PF, Kashefi SN, et al. Both MC1 and MC3 receptors provide protection from cerebral ischemia-reperfusion-induced neutrophil recruitment and barrier disruption in vivo. J Cereb Blood Flow Metab. 2015;35(12):2062-2071.\u003C\u002Fp>\n","TLP-KLOW-80MG","140",[],8,{"length":59,"width":59,"height":59},[],[],[472],{"id":78,"name":79,"slug":80},[],[],[476,477],{"id":85,"date_created":86,"date_created_gmt":86,"date_modified":87,"date_modified_gmt":87,"src":88,"name":89,"alt":59,"srcset":90,"sizes":91,"thumbnail":92},{"id":478,"date_created":479,"date_created_gmt":479,"date_modified":479,"date_modified_gmt":479,"src":480,"name":481,"alt":59,"srcset":482,"sizes":483,"thumbnail":484},3047,"2026-02-03T22:47:51","https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F3f921c6d488b8d928015.png","3f921c6d488b8d928015","https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F3f921c6d488b8d928015-200x295.png 200w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F3f921c6d488b8d928015-203x300.png 203w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F3f921c6d488b8d928015-400x590.png 400w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F3f921c6d488b8d928015-500x738.png 500w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F3f921c6d488b8d928015-600x885.png 600w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F3f921c6d488b8d928015-694x1024.png 694w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F3f921c6d488b8d928015-700x1033.png 700w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F3f921c6d488b8d928015-768x1133.png 768w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F3f921c6d488b8d928015-800x1180.png 800w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F3f921c6d488b8d928015-1041x1536.png 1041w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F3f921c6d488b8d928015-1200x1770.png 1200w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F3f921c6d488b8d928015-1388x2048.png 1388w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F3f921c6d488b8d928015.png 1600w","(max-width: 1600px) 100vw, 1600px","https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F3f921c6d488b8d928015-500x738.png",[486],{"id":72,"name":95,"slug":95,"position":72,"visible":64,"variation":64,"options":487},[488],"80mg",[490],{"id":72,"name":95,"option":488},[492],2950,[],"\u003Cspan class=\"woocommerce-Price-amount amount\">\u003Cbdi>\u003Cspan class=\"woocommerce-Price-currencySymbol\">$\u003C\u002Fspan>140.00\u003C\u002Fbdi>\u003C\u002Fspan>",[107,194,109,262,106],[497,500,503,505,507,509],{"id":498,"key":127,"value":499},9224,{"slider_visibility":129,"slider_type":70,"wooslider":130,"page_title_bar":131},{"id":501,"key":134,"value":502},9225,"64",{"id":504,"key":138,"value":114},9226,{"id":506,"key":141,"value":142},9227,{"id":508,"key":113,"value":114},9542,{"id":510,"key":145,"value":338},9878,{"self":512,"collection":517},[513],{"href":514,"targetHints":515},"https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-json\u002Fwc\u002Fv3\u002Fproducts\u002F2836",{"allow":516},[156,157,158,159,160],[518],{"href":163},{"id":193,"name":520,"slug":521,"permalink":522,"date_created":523,"date_created_gmt":523,"date_modified":524,"date_modified_gmt":524,"type":56,"status":57,"featured":22,"catalog_visibility":58,"description":525,"short_description":60,"sku":526,"price":527,"regular_price":59,"sale_price":59,"date_on_sale_from":63,"date_on_sale_from_gmt":63,"date_on_sale_to":63,"date_on_sale_to_gmt":63,"on_sale":22,"purchasable":64,"total_sales":72,"virtual":22,"downloadable":22,"downloads":528,"download_limit":67,"download_expiry":67,"external_url":59,"button_text":59,"tax_status":68,"tax_class":59,"manage_stock":64,"stock_quantity":529,"backorders":70,"backorders_allowed":22,"backordered":22,"low_stock_amount":63,"sold_individually":22,"weight":59,"dimensions":530,"shipping_required":64,"shipping_taxable":64,"shipping_class":59,"shipping_class_id":72,"reviews_allowed":64,"average_rating":73,"rating_count":72,"upsell_ids":531,"cross_sell_ids":532,"parent_id":72,"purchase_note":59,"categories":533,"brands":535,"tags":536,"images":537,"attributes":546,"default_attributes":550,"variations":552,"grouped_products":554,"menu_order":72,"price_html":555,"related_ids":556,"meta_data":557,"stock_status":149,"has_options":64,"post_password":59,"global_unique_id":59,"jetpack_sharing_enabled":64,"_links":573},"Glow","glow","https:\u002F\u002Fapi.tlpeptides.com\u002Fproduct\u002Fglow\u002F","2025-12-02T04:46:49","2026-05-18T18:07:04","\u003Ch2>GHK-Cu Peptide\u003C\u002Fh2>\n\u003Cp>GHK-Cu (glycyl-L-histidyl-L-lysine-copper(II)) is a naturally occurring copper-binding peptide complex found in human plasma, saliva, and urine. This tripeptide-copper complex has been extensively investigated for its potential roles in tissue repair, wound healing, skin regeneration, and anti-aging applications across various research models.\u003C\u002Fp>\n\u003Cp>GHK-Cu consists of three amino acids—glycine, histidine, and lysine—with a high affinity for copper ions (Cu2+). The peptide was first isolated from human plasma and identified as a growth-modulating factor. Research has demonstrated that GHK-Cu levels decline with age, decreasing from approximately 200 ng\u002FmL at age 20 to about 80 ng\u002FmL by age 60, prompting investigations into its potential therapeutic applications.(1)\u003C\u002Fp>\n\u003Ch2>Overview\u003C\u002Fh2>\n\u003Cp>GHK-Cu has been extensively investigated for its multifunctional biological activities, including stimulation of collagen and glycosaminoglycan synthesis, promotion of angiogenesis, modulation of metalloproteinase activity, and anti-inflammatory effects. Research indicates that the copper complex exhibits significantly greater biological activity compared to the peptide alone, suggesting that copper coordination is essential for many of its functions.(2)\u003C\u002Fp>\n\u003Cp>Studies have demonstrated that GHK-Cu influences gene expression patterns, affecting thousands of genes involved in tissue remodeling, antioxidant responses, and cellular signaling. The peptide-copper complex has been investigated for applications in dermatology, wound care, hair growth, and systemic anti-aging interventions.(3)\u003C\u002Fp>\n\u003Ch2>Chemical Makeup\u003C\u002Fh2>\n\u003Cp>Molecular Formula: C14H22N6O4Cu\u003Cbr \u002F>\nMolecular Weight: 401.91 g\u002Fmol (copper complex)\u003Cbr \u002F>\nSequence: Gly-His-Lys-Cu2+ (H-GHK-Cu-OH)\u003Cbr \u002F>\nOther Known Titles: Copper peptide, Copper tripeptide-1, Growth-modulating peptide\u003C\u002Fp>\n\u003Ch2>Research and Clinical Studies\u003C\u002Fh2>\n\u003Ch3>GHK-Cu and Wound Healing\u003C\u002Fh3>\n\u003Cp>Research examining GHK-Cu in wound healing has demonstrated accelerated tissue repair across multiple experimental models. Studies indicated that GHK-Cu application appeared to increase the rate of wound closure, enhance granulation tissue formation, and improve the quality of healed tissue compared to control treatments.(4)\u003C\u002Fp>\n\u003Cp>Investigations into cellular mechanisms suggested that GHK-Cu may stimulate fibroblast proliferation and migration, processes critical for wound repair. Research demonstrated increased fibroblast activity and collagen deposition in wounds treated with GHK-Cu, potentially contributing to enhanced structural integrity of healing tissue.(5)\u003C\u002Fp>\n\u003Cp>Studies exploring angiogenesis in wound healing suggested that GHK-Cu may promote blood vessel formation in healing tissues. Research indicated increased vascular density and improved tissue perfusion in GHK-Cu-treated wounds, which may facilitate nutrient and oxygen delivery essential for optimal healing.(6)\u003C\u002Fp>\n\u003Ch3>GHK-Cu and Collagen Synthesis\u003C\u002Fh3>\n\u003Cp>Research investigating GHK-Cu's effects on collagen production has consistently demonstrated stimulatory effects. Studies in cultured fibroblasts indicated that GHK-Cu treatment appeared to increase collagen type I synthesis, the predominant collagen in skin and connective tissues.(7)\u003C\u002Fp>\n\u003Cp>Investigations examining glycosaminoglycan synthesis suggested that GHK-Cu may also enhance production of these extracellular matrix components. Research indicated increased synthesis of dermatan sulfate and other glycosaminoglycans, which contribute to tissue hydration and structural organization.(8)\u003C\u002Fp>\n\u003Cp>Studies exploring molecular mechanisms suggested that GHK-Cu may influence collagen synthesis through multiple pathways, including stimulation of transforming growth factor-beta (TGF-β) and modulation of gene expression patterns related to extracellular matrix production.(9)\u003C\u002Fp>\n\u003Ch3>GHK-Cu and Skin Regeneration\u003C\u002Fh3>\n\u003Cp>Research examining GHK-Cu in skin aging has demonstrated multiple beneficial effects on aged skin. Studies indicated that topical GHK-Cu application appeared to increase skin thickness, improve skin density, and enhance overall skin appearance in both animal models and human subjects.(10)\u003C\u002Fp>\n\u003Cp>Investigations into photoaging suggested that GHK-Cu may address ultraviolet radiation-induced skin damage. Research demonstrated improvements in fine lines, wrinkles, skin laxity, and pigmentation irregularities following GHK-Cu treatment in photoaged skin.(11)\u003C\u002Fp>\n\u003Cp>Studies exploring skin barrier function suggested that GHK-Cu may enhance epidermal barrier integrity. Research indicated improvements in transepidermal water loss measurements and increased expression of barrier-related proteins, potentially contributing to improved skin hydration and protection.(12)\u003C\u002Fp>\n\u003Ch3>GHK-Cu and Metalloproteinase Regulation\u003C\u002Fh3>\n\u003Cp>Research investigating GHK-Cu's effects on matrix metalloproteinases (MMPs) has revealed complex regulatory activities. Studies indicated that GHK-Cu may reduce excessive MMP activity in damaged or aged tissues while maintaining appropriate levels for normal tissue remodeling.(13)\u003C\u002Fp>\n\u003Cp>Investigations examining specific MMPs suggested that GHK-Cu may decrease MMP-1 (collagenase) and MMP-2 (gelatinase) activity in certain contexts. Research indicated that this modulation may prevent excessive collagen degradation while promoting appropriate extracellular matrix turnover.(14)\u003C\u002Fp>\n\u003Cp>Studies exploring tissue inhibitors of metalloproteinases (TIMPs) suggested that GHK-Cu may influence the MMP\u002FTIMP balance. Research demonstrated increased TIMP expression in some experimental models, potentially contributing to preservation of extracellular matrix integrity.(15)\u003C\u002Fp>\n\u003Ch3>GHK-Cu and Anti-Inflammatory Effects\u003C\u002Fh3>\n\u003Cp>Research examining GHK-Cu's inflammatory modulation has demonstrated anti-inflammatory properties across various models. Studies indicated that GHK-Cu treatment appeared to reduce pro-inflammatory cytokine production, including interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α).(16)\u003C\u002Fp>\n\u003Cp>Investigations into inflammatory signaling pathways suggested that GHK-Cu may inhibit nuclear factor kappa B (NF-κB) activation. Research indicated reduced NF-κB nuclear translocation and decreased expression of NF-κB-dependent inflammatory genes in cells treated with GHK-Cu.(17)\u003C\u002Fp>\n\u003Cp>Studies exploring oxidative stress suggested that GHK-Cu may exhibit antioxidant properties. Research demonstrated increased expression of antioxidant enzymes and reduced markers of oxidative damage in tissues treated with the peptide-copper complex.(18)\u003C\u002Fp>\n\u003Ch3>GHK-Cu and Gene Expression\u003C\u002Fh3>\n\u003Cp>Research investigating GHK-Cu's effects on gene expression has revealed extensive regulatory activities. Studies utilizing gene microarray analysis indicated that GHK-Cu treatment affected expression of over 30% of human genes, with particularly strong effects on genes involved in tissue remodeling and cellular responses to stress.(3)\u003C\u002Fp>\n\u003Cp>Investigations into specific gene categories suggested that GHK-Cu may upregulate genes involved in antioxidant responses, DNA repair, and protein folding while downregulating genes associated with inflammation, fibrosis, and oxidative damage. Research indicated that these expression patterns may contribute to tissue regeneration and anti-aging effects.(3)\u003C\u002Fp>\n\u003Cp>Studies examining epigenetic mechanisms suggested that GHK-Cu may influence chromatin remodeling and gene accessibility. Research indicated potential effects on histone modifications and DNA methylation patterns, though mechanisms require further investigation.(19)\u003C\u002Fp>\n\u003Ch3>GHK-Cu and Hair Growth\u003C\u002Fh3>\n\u003Cp>Research examining GHK-Cu in hair biology has suggested potential applications for hair loss conditions. Studies indicated that GHK-Cu treatment appeared to increase hair follicle size, prolong the anagen (growth) phase, and stimulate hair growth in some experimental models.(20)\u003C\u002Fp>\n\u003Cp>Investigations into mechanisms suggested that GHK-Cu may influence hair follicle stem cell activity and dermal papilla cell function. Research demonstrated increased proliferation of follicular cells and enhanced expression of growth factors associated with hair follicle cycling.(20)\u003C\u002Fp>\n\u003Ch3>GHK-Cu and Nervous System\u003C\u002Fh3>\n\u003Cp>Research investigating GHK-Cu in nervous tissue has explored potential neuroprotective and neuroregenerative effects. Studies indicated that GHK-Cu treatment appeared to support neurite outgrowth and protect neurons from various stress conditions in cell culture models.(2)\u003C\u002Fp>\n\u003Cp>Investigations into nerve regeneration suggested that GHK-Cu may promote peripheral nerve repair. Research in nerve injury models demonstrated improved functional recovery and enhanced nerve regeneration with GHK-Cu treatment, though mechanisms appeared complex and multifactorial.(2)\u003C\u002Fp>\n\u003Ch3>GHK-Cu Delivery and Formulation\u003C\u002Fh3>\n\u003Cp>Research investigating optimal delivery methods for GHK-Cu has explored various formulation strategies. Studies examining topical delivery indicated that appropriate vehicle selection, pH optimization, and penetration enhancement strategies may improve GHK-Cu efficacy in dermatological applications.(10)\u003C\u002Fp>\n\u003Cp>Investigations into stability considerations suggested that GHK-Cu formulations require careful attention to copper coordination and oxidation prevention. Research indicated that proper formulation techniques may preserve peptide-copper complex integrity and maintain biological activity during storage and application.(1)\u003C\u002Fp>\n\u003Cp>Studies exploring alternative delivery routes, including subcutaneous and systemic administration, have examined biodistribution and systemic effects. Research indicated that delivery route selection may influence the spectrum of biological effects and therapeutic applications.(2)\u003C\u002Fp>\n\u003Ch3>GHK-Cu Safety and Tolerability\u003C\u002Fh3>\n\u003Cp>Research investigating GHK-Cu's safety profile has generally indicated favorable tolerability in preclinical and clinical studies. Studies examining topical application reported minimal adverse reactions, with most investigations noting excellent skin tolerability across various concentrations and formulations.(10)\u003C\u002Fp>\n\u003Cp>Investigations into systemic effects following topical application suggested minimal systemic absorption due to the peptide's relatively large size and charged nature. Research indicated that GHK-Cu primarily exerts local effects when applied topically, contributing to its favorable safety profile.(11)\u003C\u002Fp>\n\u003Cp>Studies examining long-term use in dermatological applications have reported sustained benefits without evidence of tolerance development or cumulative toxicity. Research indicated that repeated GHK-Cu application maintained efficacy over extended treatment periods.(11)\u003C\u002Fp>\n\u003Cp>Available for Research Purposes Only\u003C\u002Fp>\n\u003Cp>GHK-Cu peptide complex is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.\u003C\u002Fp>\n\u003Ch2>References\u003C\u002Fh2>\n\u003Cp>1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987.\u003C\u002Fp>\n\u003Cp>2. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-988.\u003C\u002Fp>\n\u003Cp>3. Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev. 2012;2012:324832.\u003C\u002Fp>\n\u003Cp>4. Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994;2(4):259-269.\u003C\u002Fp>\n\u003Cp>5. Pollard JD, Quan S, Kang T, Koch RJ. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Arch Facial Plast Surg. 2005;7(1):27-31.\u003C\u002Fp>\n\u003Cp>6. Siméon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;67(18):2257-2265.\u003C\u002Fp>\n\u003Cp>7. McCormack MC, Nowak KC, Koch RJ. The effect of copper tripeptide and tretinoin on growth factor production in a serum-free fibroblast model. Arch Facial Plast Surg. 2001;3(1):28-32.\u003C\u002Fp>\n\u003Cp>8. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-346.\u003C\u002Fp>\n\u003Cp>9. Grether-Beck S, Felsner I, Brenden H, et al. Urea uptake enhances barrier function and antimicrobial defense in humans by regulating epidermal gene expression. J Invest Dermatol. 2012;132(6):1561-1572.\u003C\u002Fp>\n\u003Cp>10. Appa ZH, Barkovic S, Pickart L. Skin Regenerative and Anti-Cancer Actions of Copper Peptides. Cosmetics. 2018;5(2):29.\u003C\u002Fp>\n\u003Cp>11. Finkley MB, Appa Y, Bhandarkar S. Copper peptide and skin. Cosmeceuticals and Active Cosmetics. 2005:549-563.\u003C\u002Fp>\n\u003Cp>12. Wegrowski Y, Maquart FX, Borel JP. Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. Life Sci. 1992;51(13):1049-1056.\u003C\u002Fp>\n\u003Cp>13. Kang YA, Choi HR, Na JI, et al. Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Arch Dermatol Res. 2009;301(4):301-306.\u003C\u002Fp>\n\u003Cp>14. Siméon A, Monier F, Emonard H, et al. Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). J Invest Dermatol. 1999;112(6):957-964.\u003C\u002Fp>\n\u003Cp>15. Lovejoy B, Cleasby A, Hassell AM, et al. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. Science. 1994;263(5145):375-377.\u003C\u002Fp>\n\u003Cp>16. Miller J, Djabali K, Chen T, et al. Atopy patch test reactions show augmented IL-16 expression and decreased keratinocyte cell differentiation. J Am Acad Dermatol. 2005;52(3 Pt 1):468-478.\u003C\u002Fp>\n\u003Cp>17. Choi HR, Kang YA, Ryoo SJ, Shin JW, Na JI, Huh CH, Park KC. Involvement of the p38 mitogen-activated protein kinase pathway in the induction of melanogenesis by alpha-melanocyte-stimulating hormone. Arch Dermatol Res. 2011;303(7):513-519.\u003C\u002Fp>\n\u003Cp>18. Park JR, Lee H, Kim SI, Yang SR. The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice. Oncotarget. 2016;7(36):58405-58417.\u003C\u002Fp>\n\u003Cp>19. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108.\u003C\u002Fp>\n\u003Cp>20. Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007;30(7):834-839.\u003C\u002Fp>\n","TLP-GLOW-70MG","128",[],10,{"length":59,"width":59,"height":59},[],[],[534],{"id":78,"name":79,"slug":80},[],[],[538,539],{"id":85,"date_created":86,"date_created_gmt":86,"date_modified":87,"date_modified_gmt":87,"src":88,"name":89,"alt":59,"srcset":90,"sizes":91,"thumbnail":92},{"id":540,"date_created":541,"date_created_gmt":541,"date_modified":541,"date_modified_gmt":541,"src":542,"name":543,"alt":59,"srcset":544,"sizes":483,"thumbnail":545},3046,"2026-02-03T22:47:46","https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F37c866b95d2303f4a5d1.png","37c866b95d2303f4a5d1","https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F37c866b95d2303f4a5d1-200x295.png 200w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F37c866b95d2303f4a5d1-203x300.png 203w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F37c866b95d2303f4a5d1-400x590.png 400w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F37c866b95d2303f4a5d1-500x738.png 500w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F37c866b95d2303f4a5d1-600x885.png 600w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F37c866b95d2303f4a5d1-694x1024.png 694w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F37c866b95d2303f4a5d1-700x1033.png 700w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F37c866b95d2303f4a5d1-768x1133.png 768w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F37c866b95d2303f4a5d1-800x1180.png 800w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F37c866b95d2303f4a5d1-1041x1536.png 1041w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F37c866b95d2303f4a5d1-1200x1770.png 1200w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F37c866b95d2303f4a5d1-1388x2048.png 1388w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F37c866b95d2303f4a5d1.png 1600w","https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F37c866b95d2303f4a5d1-500x738.png",[547],{"id":72,"name":95,"slug":95,"position":72,"visible":64,"variation":64,"options":548},[549,311],"70mg",[551],{"id":72,"name":95,"option":549},[553],2952,[],"\u003Cspan class=\"woocommerce-Price-amount amount\">\u003Cbdi>\u003Cspan class=\"woocommerce-Price-currencySymbol\">$\u003C\u002Fspan>128.00\u003C\u002Fbdi>\u003C\u002Fspan>",[194,50,109,108,262],[558,561,564,566,568,570],{"id":559,"key":127,"value":560},9199,{"slider_visibility":129,"slider_type":70,"wooslider":130,"page_title_bar":131},{"id":562,"key":134,"value":563},9200,"69",{"id":565,"key":138,"value":114},9201,{"id":567,"key":141,"value":142},9202,{"id":569,"key":113,"value":114},9543,{"id":571,"key":145,"value":572},9896,"17",{"self":574,"collection":579},[575],{"href":576,"targetHints":577},"https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-json\u002Fwc\u002Fv3\u002Fproducts\u002F2835",{"allow":578},[156,157,158,159,160],[580],{"href":163},{"id":106,"name":582,"slug":583,"permalink":584,"date_created":585,"date_created_gmt":585,"date_modified":586,"date_modified_gmt":586,"type":56,"status":57,"featured":22,"catalog_visibility":58,"description":587,"short_description":60,"sku":59,"price":588,"regular_price":59,"sale_price":59,"date_on_sale_from":63,"date_on_sale_from_gmt":63,"date_on_sale_to":63,"date_on_sale_to_gmt":63,"on_sale":22,"purchasable":64,"total_sales":589,"virtual":22,"downloadable":22,"downloads":590,"download_limit":67,"download_expiry":67,"external_url":59,"button_text":59,"tax_status":68,"tax_class":59,"manage_stock":22,"stock_quantity":63,"backorders":70,"backorders_allowed":22,"backordered":22,"low_stock_amount":63,"sold_individually":22,"weight":59,"dimensions":591,"shipping_required":64,"shipping_taxable":64,"shipping_class":59,"shipping_class_id":72,"reviews_allowed":64,"average_rating":73,"rating_count":72,"upsell_ids":592,"cross_sell_ids":593,"parent_id":72,"purchase_note":59,"categories":594,"brands":596,"tags":597,"images":600,"attributes":609,"default_attributes":615,"variations":617,"grouped_products":620,"menu_order":72,"price_html":621,"related_ids":622,"meta_data":623,"stock_status":149,"has_options":64,"post_password":59,"global_unique_id":59,"jetpack_sharing_enabled":64,"_links":638},"Retatrutide","retatrutide","https:\u002F\u002Fapi.tlpeptides.com\u002Fproduct\u002Fretatrutide\u002F","2025-12-02T04:44:07","2026-05-18T18:57:31","\u003Ch2>Retatrutide Peptide\u003C\u002Fh2>\n\u003Cp>Retatrutide is a synthetic peptide that has been investigated in various research studies for its potential effects on glucose metabolism, body weight regulation, and metabolic parameters. The compound functions as a triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors.\u003C\u002Fp>\n\u003Cp>Retatrutide is a synthetic peptide composed of 39 amino acids engineered from a GIP peptide backbone to stimulate GLP-1, GIP, and glucagon receptors. The peptide incorporates a C20 fatty diacid moiety conjugated through a hydrophilic linker, which extends its half-life to approximately 6 days, allowing for once-weekly administration.(1)\u003C\u002Fp>\n\u003Ch2>Overview\u003C\u002Fh2>\n\u003Cp>Retatrutide has been investigated for its potential in metabolic regulation through its triple receptor agonism mechanism. Studies suggest that the peptide may stimulate insulin secretion from pancreatic beta cells while modulating glucagon release and influencing energy expenditure. The compound appears to bind with GLP-1, GIP, and glucagon receptors, potentially initiating multiple signaling cascades that influence metabolic function.(2)\u003C\u002Fp>\n\u003Cp>Research has explored retatrutide's action across diverse metabolic pathways. The peptide has been studied for its potential effects on glucose homeostasis, body weight regulation, appetite control, hepatic lipid metabolism, and energy expenditure. Laboratory investigations indicate the compound may influence metabolic balance through both central and peripheral mechanisms.(3)\u003C\u002Fp>\n\u003Cp>Studies have suggested the peptide may enhance beta-cell function, improve markers of insulin sensitivity, and promote hepatic fat oxidation. The triple receptor activation appears to provide synergistic effects on glucose-dependent insulin secretion, appetite regulation, gastric emptying, and substrate utilization.(4)\u003C\u002Fp>\n\u003Ch2>Chemical Makeup\u003C\u002Fh2>\n\u003Cp>\u003Cstrong>Molecular Formula:\u003C\u002Fstrong> C208H338N56O68S\u003Cbr \u002F>\n\u003Cstrong>Molecular Weight:\u003C\u002Fstrong> 4813.5 g\u002Fmol (approximate)\u003Cbr \u002F>\n\u003Cstrong>Other Known Titles:\u003C\u002Fstrong> LY3437943\u003C\u002Fp>\n\u003Ch2>Research and Clinical Studies\u003C\u002Fh2>\n\u003Ch3>Retatrutide Peptide and Glucose Metabolism\u003C\u002Fh3>\n\u003Cp>In research studies examining metabolic function, retatrutide was investigated for its potential effects on glucose regulation and insulin secretion. The compound appeared to enhance glucose-dependent insulin secretion while reducing glucagon levels. Research suggested that retatrutide may preferentially stimulate insulin release during hyperglycemic conditions while maintaining glucose-dependent mechanisms.(5)\u003C\u002Fp>\n\u003Cp>Studies examining glycemic control indicated that retatrutide appeared to reduce HbA1c levels in a dose-dependent manner. Research in models with type 2 diabetes suggested reductions ranging from 1.3% to 2.2% at 24 weeks with doses from 4 mg to 12 mg. These reductions appeared superior to those observed with comparator GLP-1 receptor agonists.(6)\u003C\u002Fp>\n\u003Cp>Investigations examining glucose tolerance suggested that retatrutide may improve both fasting and postprandial glucose concentrations. Research indicated reductions in daily mean blood glucose levels, suggesting comprehensive effects on glucose homeostasis throughout the day.(7)\u003C\u002Fp>\n\u003Ch3>Retatrutide Peptide and Beta-Cell Function\u003C\u002Fh3>\n\u003Cp>A study examining beta-cell function markers investigated retatrutide's potential effects on pancreatic beta-cell responsiveness. Research evaluating homeostatic model assessment indices suggested that retatrutide appeared to improve HOMA-B (beta-cell function) markers in research models with type 2 diabetes.(8)\u003C\u002Fp>\n\u003Cp>Investigations suggested that retatrutide may reduce fasting proinsulin levels and improve proinsulin-to-insulin ratios. Research indicated that these improvements in proinsulin processing may reflect enhanced beta-cell function and reduced beta-cell stress.(9)\u003C\u002Fp>\n\u003Cp>Studies examining insulin secretion patterns suggested that retatrutide may enhance both first- and second-phase insulin responses. Research indicated that the compound's effects on beta-cell function appeared to be sustained over extended treatment periods.(8)\u003C\u002Fp>\n\u003Ch3>Retatrutide Peptide and Insulin Sensitivity\u003C\u002Fh3>\n\u003Cp>Research examining insulin sensitivity markers suggested that retatrutide may improve multiple biomarkers associated with insulin resistance. Studies indicated reductions in HOMA-IR indices, with research showing improvements of up to 69% from baseline measurements.(10)\u003C\u002Fp>\n\u003Cp>Investigations examining fasting insulin and C-peptide concentrations suggested dose-dependent reductions with retatrutide administration. Research indicated that fasting insulin levels appeared to decrease by up to 70% with higher doses, while C-peptide concentrations decreased by up to 50%.(10)\u003C\u002Fp>\n\u003Cp>Studies suggested that improvements in insulin sensitivity with retatrutide were only partially explained by weight loss. Research indicated that weight changes accounted for a portion of insulin resistance improvements, suggesting the triple receptor agonism may confer distinct metabolic effects independent of weight reduction.(11)\u003C\u002Fp>\n\u003Ch3>Retatrutide Peptide and Body Weight Regulation\u003C\u002Fh3>\n\u003Cp>Research examining body weight changes suggested that retatrutide may influence weight through multiple mechanisms including reduced energy intake, delayed gastric emptying, and increased energy expenditure. Long-term investigations spanning 48 weeks indicated substantial body weight reductions ranging from 8.7% to 24.2% depending on the dose administered.(12)\u003C\u002Fp>\n\u003Cp>Studies indicated that at the 12 mg dose, weight reductions of 24.2% were observed at 48 weeks, with participants continuing to lose weight without reaching a plateau. Research suggested that more than 90% of participants receiving 12 mg achieved weight loss of at least 10%, while approximately 83% achieved reductions of 15% or more.(12)\u003C\u002Fp>\n\u003Cp>Investigations examining weight loss responders indicated dose-dependent effects. Research suggested that with the 8 mg dose, 100% of participants achieved at least 5% weight loss, 91% achieved at least 10%, and 75% achieved at least 15% weight reduction.(12)\u003C\u002Fp>\n\u003Ch3>Retatrutide Peptide and Body Composition\u003C\u002Fh3>\n\u003Cp>Research examining body composition changes suggested that retatrutide may preferentially reduce fat mass while preserving lean mass. Studies utilizing dual-energy X-ray absorptiometry indicated that total fat mass reductions ranged from 15.2% to 26.1% depending on dose, with higher doses associated with greater fat mass reduction.(13)\u003C\u002Fp>\n\u003Cp>Investigations suggested that the proportion of lean mass loss to total weight loss with retatrutide appeared similar to other obesity treatments. Research indicated approximately 25-40% of weight loss derived from lean mass, with the majority coming from fat mass reduction.(13)\u003C\u002Fp>\n\u003Cp>Studies examining visceral adipose tissue suggested that retatrutide appeared to reduce abdominal and visceral fat deposits. Research indicated that waist circumference reductions were observed across all dose groups, suggesting effects on central adiposity.(14)\u003C\u002Fp>\n\u003Ch3>Retatrutide Peptide and Hepatic Parameters\u003C\u002Fh3>\n\u003Cp>Research examining liver fat content suggested that retatrutide may substantially reduce hepatic steatosis. Studies in models with metabolic dysfunction-associated steatotic liver disease indicated relative liver fat reductions of 42.9% to 82.4% at 24 weeks depending on dose.(15)\u003C\u002Fp>\n\u003Cp>Investigations suggested that with the 8 mg and 12 mg doses, liver fat reductions exceeded 80% from baseline measurements. Research indicated that most liver fat reduction occurred within the first 24 weeks of treatment, with sustained reductions maintained through 48 weeks.(15)\u003C\u002Fp>\n\u003Cp>Studies examining markers of liver injury suggested that retatrutide may improve alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. Research indicated improvements in fibrosis markers including FIB-4 index and Enhanced Liver Fibrosis scores.(15)\u003C\u002Fp>\n\u003Ch3>Retatrutide Peptide and Lipid Metabolism\u003C\u002Fh3>\n\u003Cp>Research examining lipid parameters suggested that retatrutide may influence multiple aspects of lipid metabolism. Studies indicated potential reductions in triglycerides, with research showing decreases of more than 40% at higher doses.(16)\u003C\u002Fp>\n\u003Cp>Investigations suggested that very low-density lipoprotein cholesterol (VLDL-C) and non-HDL cholesterol appeared to decrease with retatrutide treatment. Research in models with obesity indicated improvements in overall lipid profiles across multiple parameters.(16)\u003C\u002Fp>\n\u003Cp>Studies examining the relationship between lipid changes and liver fat suggested that triglyceride reductions were significantly associated with hepatic fat improvements. Research indicated that lipid metabolism improvements may contribute to overall metabolic health benefits.(15)\u003C\u002Fp>\n\u003Ch3>Retatrutide Peptide and Energy Expenditure\u003C\u002Fh3>\n\u003Cp>Research investigating energy balance suggested that retatrutide's glucagon receptor activation may enhance energy expenditure beyond effects on energy intake alone. Studies indicated that the glucagon component may promote fatty acid oxidation and thermogenic activity.(17)\u003C\u002Fp>\n\u003Cp>Investigations suggested that retatrutide may influence substrate utilization, potentially shifting metabolism toward increased fat oxidation. Research indicated that the compound's effects on glucagon receptors may enhance lipolysis and hepatic lipid oxidation.(18)\u003C\u002Fp>\n\u003Ch3>Retatrutide Peptide and Gastric Emptying\u003C\u002Fh3>\n\u003Cp>Studies examining gastric motility suggested that retatrutide may delay gastric emptying in a dose-dependent manner. Research in animal models indicated that the compound appeared to slow gastric emptying, with effects mediated primarily through GLP-1 receptor activation.(19)\u003C\u002Fp>\n\u003Cp>Investigations suggested that chronic treatment may lead to some attenuation of gastric emptying effects over time. Research indicated a pattern consistent with tachyphylaxis observed with other long-acting GLP-1 receptor agonists.(19)\u003C\u002Fp>\n\u003Ch3>Retatrutide Peptide and Appetite Regulation\u003C\u002Fh3>\n\u003Cp>Research investigating appetite and food intake suggested that retatrutide may reduce energy consumption through effects on appetite-regulating centers in the brain. Studies indicated that the compound may access hypothalamic regions involved in hunger and satiety signaling.(20)\u003C\u002Fp>\n\u003Cp>Investigations suggested that retatrutide may reduce food intake beyond effects attributable to delayed gastric emptying alone. Research indicated dose-dependent reductions in food consumption in preclinical models, with effects sustained over chronic treatment periods.(19)\u003C\u002Fp>\n\u003Ch3>Retatrutide Peptide and Cardiovascular Parameters\u003C\u002Fh3>\n\u003Cp>Studies examining cardiovascular risk markers suggested that retatrutide may influence blood pressure parameters. Research indicated reductions in systolic blood pressure with retatrutide administration, suggesting potential cardiovascular benefits.(21)\u003C\u002Fp>\n\u003Cp>Investigations examining inflammatory markers suggested that retatrutide may reduce pro-inflammatory cytokines. Research indicated improvements in markers associated with cardiovascular health, though long-term cardiovascular outcome studies are ongoing.(22)\u003C\u002Fp>\n\u003Ch3>Retatrutide Peptide and Renal Function\u003C\u002Fh3>\n\u003Cp>Research examining kidney function in diabetic models suggested that retatrutide may influence markers of diabetic kidney disease. Studies in animal models indicated potential improvements in albuminuria and glomerular filtration markers.(23)\u003C\u002Fp>\n\u003Cp>Investigations comparing retatrutide with other incretin-based therapies suggested potentially superior effects on renal parameters in preclinical models. Research indicated improvements in kidney structure and function markers in diabetic research models.(23)\u003C\u002Fp>\n\u003Ch3>Retatrutide Peptide and Receptor Pharmacology\u003C\u002Fh3>\n\u003Cp>Studies examining receptor binding characteristics indicated that retatrutide demonstrates differential potency across its three target receptors. Research suggested the compound is most potent at the human GIP receptor (EC50: 0.0643 nM), moderately potent at the GLP-1 receptor (EC50: 0.775 nM), and least potent at the glucagon receptor (EC50: 5.79 nM).(24)\u003C\u002Fp>\n\u003Cp>Investigations into molecular structure suggested that retatrutide develops a single continuous helical structure allowing it to engage receptor transmembrane domains. Research indicated that the N-terminal segment runs through the receptor's transmembrane domain, while the C-terminal segment interacts with extracellular components.(24)\u003C\u002Fp>\n\u003Ch3>Retatrutide Peptide and Molecular Mechanisms\u003C\u002Fh3>\n\u003Cp>Research examining intracellular signaling pathways suggested that retatrutide activates multiple downstream cascades. Studies indicated that GLP-1 receptor activation may increase intracellular cAMP levels, activating protein kinase A and exchange protein directly activated by cAMP.(25)\u003C\u002Fp>\n\u003Cp>Investigations suggested that glucagon receptor activation may promote hepatic gluconeogenesis suppression and enhance fatty acid oxidation. Research indicated that this mechanism may contribute to liver fat reduction beyond weight loss effects.(15)\u003C\u002Fp>\n\u003Cp>Studies examining the synergistic effects of triple agonism suggested that combining GLP-1, GIP, and glucagon receptor activation may provide complementary metabolic benefits. Research indicated that this multi-receptor approach may enhance effects on energy intake, substrate utilization, and energy expenditure compared to single or dual receptor agonism.(26)\u003C\u002Fp>\n\u003Ch2>Available for Research Purposes Only\u003C\u002Fh2>\n\u003Cp>Retatrutide peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.\u003C\u002Fp>\n\u003Chr \u002F>\n\u003Ch2>References\u003C\u002Fh2>\n\u003Col>\n\u003Cli>Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9.\u003C\u002Fli>\n\u003Cli>Urva S, Coskun T, Loghin C, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881.\u003C\u002Fli>\n\u003Cli>Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.\u003C\u002Fli>\n\u003Cli>Hartman ML, Sanyal AJ, Loomba R, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(6):1636-1645.\u003C\u002Fli>\n\u003Cli>Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544.\u003C\u002Fli>\n\u003Cli>Coskun T, Wu Q, Lou J, et al. Retatrutide, an Agonist of GIP, GLP-1, and Glucagon Receptors, Improves Markers of Pancreatic Beta-Cell Function and Insulin Sensitivity. Diabetes. 2024;73(Supplement_1):266-OR.\u003C\u002Fli>\n\u003Cli>Alexiadou K, Anyiam O, Tan TM. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Endocrinol Metab. 2025;16:20420188241310715.\u003C\u002Fli>\n\u003Cli>Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021;106(2):388-396.\u003C\u002Fli>\n\u003Cli>Nahra R, Wang T, Gadde KM, et al. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. Diabetes Care. 2021;44(6):1433-1442.\u003C\u002Fli>\n\u003Cli>Hartman ML, Sanyal AJ, Loomba R, et al. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes. Diabetes Care. 2020;43(6):1352-1355.\u003C\u002Fli>\n\u003Cli>Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.\u003C\u002Fli>\n\u003Cli>Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.\u003C\u002Fli>\n\u003Cli>Coskun T, Wu Q, Chae N, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025;13(1):e1-e14.\u003C\u002Fli>\n\u003Cli>Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564.\u003C\u002Fli>\n\u003Cli>Hartman ML, Sanyal AJ, Loomba R, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(6):1636-1645.\u003C\u002Fli>\n\u003Cli>Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544.\u003C\u002Fli>\n\u003Cli>Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27-36.\u003C\u002Fli>\n\u003Cli>Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5(10):749-757.\u003C\u002Fli>\n\u003Cli>Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide dose-dependent effects on gastric emptying and food intake in obesity. Diabetes Obes Metab. 2024;26(3):945-954.\u003C\u002Fli>\n\u003Cli>Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429.\u003C\u002Fli>\n\u003Cli>Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834-844.\u003C\u002Fli>\n\u003Cli>Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591-598.\u003C\u002Fli>\n\u003Cli>Ma H, Wang X, Zhang W, et al. Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, ameliorates diabetic kidney disease in db\u002Fdb mice. Pharmacol Res. 2024;199:107041.\u003C\u002Fli>\n\u003Cli>Samms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410-421.\u003C\u002Fli>\n\u003Cli>Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756.\u003C\u002Fli>\n\u003Cli>Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9.\u003C\u002Fli>\n\u003C\u002Fol>\n","125",12,[],{"length":59,"width":59,"height":59},[],[],[595],{"id":78,"name":79,"slug":80},[],[598],{"id":599,"name":582,"slug":583},76,[601,602],{"id":85,"date_created":86,"date_created_gmt":86,"date_modified":87,"date_modified_gmt":87,"src":88,"name":89,"alt":59,"srcset":90,"sizes":91,"thumbnail":92},{"id":603,"date_created":604,"date_created_gmt":604,"date_modified":604,"date_modified_gmt":604,"src":605,"name":606,"alt":59,"srcset":607,"sizes":483,"thumbnail":608},3049,"2026-02-03T22:48:02","https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F39c45511bfe7e6fdcc68.png","39c45511bfe7e6fdcc68","https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F39c45511bfe7e6fdcc68-200x295.png 200w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F39c45511bfe7e6fdcc68-203x300.png 203w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F39c45511bfe7e6fdcc68-400x590.png 400w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F39c45511bfe7e6fdcc68-500x738.png 500w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F39c45511bfe7e6fdcc68-600x885.png 600w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F39c45511bfe7e6fdcc68-694x1024.png 694w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F39c45511bfe7e6fdcc68-700x1033.png 700w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F39c45511bfe7e6fdcc68-768x1133.png 768w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F39c45511bfe7e6fdcc68-800x1180.png 800w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F39c45511bfe7e6fdcc68-1041x1536.png 1041w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F39c45511bfe7e6fdcc68-1200x1770.png 1200w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F39c45511bfe7e6fdcc68-1388x2048.png 1388w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F39c45511bfe7e6fdcc68.png 1600w","https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002F39c45511bfe7e6fdcc68-500x738.png",[610],{"id":72,"name":95,"slug":95,"position":72,"visible":64,"variation":64,"options":611},[254,97,612,613,614,311],"15mg","20mg","30mg",[616],{"id":72,"name":95,"option":612},[618,619],2943,2944,[],"\u003Cspan class=\"woocommerce-Price-amount amount\" aria-hidden=\"true\">\u003Cbdi>\u003Cspan class=\"woocommerce-Price-currencySymbol\">$\u003C\u002Fspan>125.00\u003C\u002Fbdi>\u003C\u002Fspan> \u003Cspan aria-hidden=\"true\">–\u003C\u002Fspan> \u003Cspan class=\"woocommerce-Price-amount amount\" aria-hidden=\"true\">\u003Cbdi>\u003Cspan class=\"woocommerce-Price-currencySymbol\">$\u003C\u002Fspan>185.00\u003C\u002Fbdi>\u003C\u002Fspan>\u003Cspan class=\"screen-reader-text\">Price range: $125.00 through $185.00\u003C\u002Fspan>",[320,105,193,194,262],[624,627,630,632,634,636],{"id":625,"key":127,"value":626},8996,{"slider_visibility":129,"slider_type":70,"wooslider":130,"page_title_bar":131},{"id":628,"key":134,"value":629},8997,"119",{"id":631,"key":138,"value":114},8998,{"id":633,"key":141,"value":142},8999,{"id":635,"key":145,"value":409},9756,{"id":637,"key":113,"value":114},9758,{"self":639,"collection":644},[640],{"href":641,"targetHints":642},"https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-json\u002Fwc\u002Fv3\u002Fproducts\u002F2827",{"allow":643},[156,157,158,159,160],[645],{"href":163},{"id":262,"name":647,"slug":648,"permalink":649,"date_created":650,"date_created_gmt":650,"date_modified":87,"date_modified_gmt":87,"type":56,"status":57,"featured":22,"catalog_visibility":58,"description":651,"short_description":60,"sku":652,"price":653,"regular_price":59,"sale_price":59,"date_on_sale_from":63,"date_on_sale_from_gmt":63,"date_on_sale_to":63,"date_on_sale_to_gmt":63,"on_sale":22,"purchasable":64,"total_sales":654,"virtual":22,"downloadable":22,"downloads":655,"download_limit":67,"download_expiry":67,"external_url":59,"button_text":59,"tax_status":68,"tax_class":59,"manage_stock":64,"stock_quantity":78,"backorders":70,"backorders_allowed":22,"backordered":22,"low_stock_amount":63,"sold_individually":22,"weight":59,"dimensions":656,"shipping_required":64,"shipping_taxable":64,"shipping_class":59,"shipping_class_id":72,"reviews_allowed":64,"average_rating":73,"rating_count":72,"upsell_ids":657,"cross_sell_ids":658,"parent_id":72,"purchase_note":59,"categories":659,"brands":661,"tags":662,"images":665,"attributes":674,"default_attributes":679,"variations":681,"grouped_products":683,"menu_order":72,"price_html":684,"related_ids":685,"meta_data":686,"stock_status":149,"has_options":64,"post_password":59,"global_unique_id":59,"jetpack_sharing_enabled":64,"_links":702},"Tirzepatide","tirzepatide","https:\u002F\u002Fapi.tlpeptides.com\u002Fproduct\u002Ftirzepatide\u002F","2025-12-02T04:43:41","\u003Ch2 class=\"font-claude-response-title mt-1 text-text-100\">Tirzepatide Peptide\u003C\u002Fh2>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Tirzepatide is a synthetic peptide that has been investigated in various research studies for its potential effects on glucose metabolism, body weight regulation, and metabolic parameters. The compound functions as a dual receptor agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Tirzepatide is a synthetic peptide composed of 39 amino acids with dual agonist activity at GIP and GLP-1 receptors. The structure of tirzepatide is based on the native GIP sequence with modifications including the addition of a C20 fatty diacid moiety, which extends its half-life to approximately 5 days, allowing for once-weekly administration.(1)\u003C\u002Fp>\n\u003Ch2 class=\"font-claude-response-heading text-text-100 mt-1 -mb-0.5\">Overview\u003C\u002Fh2>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Tirzepatide has been investigated for its potential in metabolic regulation through its dual receptor agonism mechanism. Studies suggest that the peptide may stimulate insulin secretion from pancreatic beta cells while modulating glucose production. The compound appears to bind with both GIP and GLP-1 receptors, potentially initiating signaling cascades that influence insulin release and metabolic function.(2)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Research has explored tirzepatide's action across multiple metabolic pathways. The peptide has been studied for its potential effects on glucose homeostasis, body weight regulation, lipid metabolism, and pancreatic beta-cell function. Laboratory investigations indicate the compound may influence appetite regulation through central nervous system pathways and affect gastric emptying rates.(3)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Studies have suggested the peptide may enhance insulin sensitivity and improve markers of beta-cell function. The dual agonist activity appears to provide complementary effects through simultaneous activation of GIP and GLP-1 receptor pathways, potentially offering broader metabolic impacts than single receptor agonists.(4)\u003C\u002Fp>\n\u003Ch2 class=\"font-claude-response-heading text-text-100 mt-1 -mb-0.5\">Chemical Makeup\u003C\u002Fh2>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">\u003Cstrong>Molecular Formula:\u003C\u002Fstrong> C225H348N48O68\u003Cbr \u002F>\n\u003Cstrong>Molecular Weight:\u003C\u002Fstrong> 4813.5 g\u002Fmol\u003Cbr \u002F>\n\u003Cstrong>Other Known Titles:\u003C\u002Fstrong> LY3298176, Twincretin\u003C\u002Fp>\n\u003Ch2 class=\"font-claude-response-heading text-text-100 mt-1 -mb-0.5\">Research and Clinical Studies\u003C\u002Fh2>\n\u003Ch3 class=\"font-claude-response-subheading text-text-100 mt-1 -mb-1.5\">Tirzepatide Peptide and Glucose Metabolism\u003C\u002Fh3>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">In research studies examining metabolic function, tirzepatide was investigated for its potential effects on glucose regulation and insulin secretion. The compound appeared to stimulate insulin release in a glucose-dependent manner, suggesting it may preferentially enhance insulin secretion when blood glucose levels are elevated.(5)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Research utilizing islet cells from human donors demonstrated that tirzepatide's activity at the GIP receptor appeared indispensable for insulin secretion. The studies indicated that when islet cells were stimulated with tirzepatide, the compound appeared to activate GIP receptors, leading to enhanced insulin release. Interestingly, the research also suggested that tirzepatide stimulated glucagon production, consistent with GIP receptor activity.(6)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Studies evaluating tirzepatide's mechanism of action suggested the compound may reduce fasting and postprandial glucose concentrations. The peptide appeared to decrease glucagon levels in a glucose-dependent manner, potentially contributing to improved glucose regulation. Research indicated that tirzepatide may enhance both first- and second-phase insulin secretion from pancreatic beta cells.(7)\u003C\u002Fp>\n\u003Ch3 class=\"font-claude-response-subheading text-text-100 mt-1 -mb-1.5\">Tirzepatide Peptide and Beta-Cell Function\u003C\u002Fh3>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">A study examining beta-cell function markers in research models with type 2 diabetes investigated tirzepatide's potential effects. Homeostatic model assessment indices for beta-cell function appeared to increase significantly with tirzepatide administration compared to control groups. The research suggested improvements in fasting proinsulin levels and proinsulin\u002FC-peptide ratios.(8)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Researchers observed that tirzepatide administration appeared to reduce fasting proinsulin levels by approximately 49-55% compared to baseline measurements. The proinsulin\u002Finsulin and proinsulin\u002FC-peptide ratios also appeared to decrease significantly. These findings suggested potential improvements in pancreatic beta-cell stress and function, as elevated proinsulin levels have been associated with beta-cell dysfunction.(8)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Research evaluating glucose-adjusted glucagon levels indicated that tirzepatide appeared to reduce these markers by 37-44% compared to control groups. The compound appeared to improve beta-cell function through multiple mechanisms, potentially including enhanced proinsulin processing and reduced beta-cell stress.(9)\u003C\u002Fp>\n\u003Ch3 class=\"font-claude-response-subheading text-text-100 mt-1 -mb-1.5\">Tirzepatide Peptide and Insulin Sensitivity\u003C\u002Fh3>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Studies investigating insulin sensitivity markers suggested that tirzepatide may improve multiple biomarkers associated with insulin resistance. Research indicated reductions in homeostatic model assessment for insulin resistance (HOMA2-IR) indices with tirzepatide administration.(10)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Adiponectin, a protein involved in glucose and lipid metabolism regulation, appeared to increase with tirzepatide treatment. Research suggested adiponectin levels increased by 16-23% from baseline measurements over 40-week study periods. Adiponectin increases have been associated with improvements in insulin sensitivity in various research contexts.(10)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Additional biomarkers including insulin-like growth factor binding proteins (IGFBP-1 and IGFBP-2) appeared to increase with tirzepatide administration. Research indicated IGFBP-2 levels increased by 38-70% from baseline, suggesting potential improvements in insulin signaling pathways. These proteins are considered markers of insulin sensitivity in research models.(11)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Investigations suggested that improvements in insulin sensitivity markers with tirzepatide were only partially attributable to weight changes. Multiple linear regression analyses indicated that weight changes explained approximately 13-21% of insulin resistance improvements, suggesting the dual receptor agonism may confer distinct metabolic effects independent of weight reduction.(11)\u003C\u002Fp>\n\u003Ch3 class=\"font-claude-response-subheading text-text-100 mt-1 -mb-1.5\">Tirzepatide Peptide and Lipid Metabolism\u003C\u002Fh3>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Research examining lipid parameters suggested that tirzepatide may influence multiple aspects of the lipid profile. Studies indicated potential reductions in total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglyceride levels with tirzepatide administration.(12)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">A meta-analysis of research studies demonstrated dose-dependent effects on lipid markers across 5, 10, and 15 mg doses. The analysis suggested increasingly pronounced improvements in cholesterol and triglyceride levels with higher doses. Research indicated that at the 15 mg dose, LDL cholesterol levels appeared to decrease, accompanied by potential improvements in LDL particle size.(13)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Studies also suggested that tirzepatide may increase high-density lipoprotein cholesterol (HDL-C) levels. Research from various clinical investigations indicated improvements in the overall lipid profile, with effects appearing in both research models with diabetes and those without diabetes.(12)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">The peptide's effects on apolipoprotein markers were also investigated. Research suggested potential reductions in apoC-III and apoB levels, which are implicated in cardiovascular risk in various research contexts. These findings indicated that tirzepatide's lipid-modifying effects may extend beyond traditional lipid parameters.(13)\u003C\u002Fp>\n\u003Ch3 class=\"font-claude-response-subheading text-text-100 mt-1 -mb-1.5\">Tirzepatide Peptide and Body Weight Regulation\u003C\u002Fh3>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Studies examining body weight changes suggested that tirzepatide may influence weight through multiple mechanisms. Research indicated the compound may affect appetite regulation, gastric emptying, and energy balance.(14)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Investigations into gastric emptying suggested that tirzepatide appeared to delay the passage of food through the digestive tract, particularly after initial doses. Research in healthy participants and those with type 2 diabetes indicated that gastric emptying delays were observed after initial administration, though some studies suggested this effect may diminish with continued exposure.(15)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Research exploring central nervous system effects suggested that GIP signaling may influence hypothalamic feeding centers. Studies indicated that tirzepatide's effects on appetite may involve both peripheral and central mechanisms, potentially contributing to reduced food intake and satiety enhancement.(14)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Long-term research studies indicated substantial body weight reductions in research participants. Investigations spanning 72 weeks suggested weight reductions ranging from 16.5% to 22.4% depending on the dose administered, with higher doses associated with greater weight changes.(2)\u003C\u002Fp>\n\u003Ch3 class=\"font-claude-response-subheading text-text-100 mt-1 -mb-1.5\">Tirzepatide Peptide and Cardiovascular Parameters\u003C\u002Fh3>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Research examining cardiovascular biomarkers suggested that tirzepatide may influence several parameters relevant to cardiovascular health. Studies indicated potential improvements in blood pressure measurements, with reductions observed in both systolic and diastolic blood pressure.(16)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">A post-hoc analysis evaluating predicted atherosclerotic cardiovascular disease (ASCVD) risk using a validated risk engine suggested that tirzepatide may reduce 10-year predicted ASCVD risk. The analysis indicated relative risk reductions ranging from 16.4% to 23.5% compared to control groups, based on modifiable risk factors including blood pressure, cholesterol levels, and other parameters.(17)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Meta-analyses of cardiovascular event data from multiple research trials suggested that tirzepatide did not increase the risk of major adverse cardiovascular events. The analyses indicated hazard ratios below 1.0 for various cardiovascular endpoints, suggesting a neutral to potentially favorable cardiovascular profile in research settings.(18)\u003C\u002Fp>\n\u003Ch3 class=\"font-claude-response-subheading text-text-100 mt-1 -mb-1.5\">Tirzepatide Peptide and Hepatic Parameters\u003C\u002Fh3>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Studies investigating hepatic markers suggested that tirzepatide may influence liver fat content and related parameters. Research indicated reductions in hepatic steatosis index, a measure associated with liver fat accumulation.(19)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Investigations in research models with diet-induced obesity suggested that tirzepatide administration appeared to reduce circulating triglyceride levels and free fatty acids while lowering hepatic fat content. These effects appeared to be accompanied by improvements in systemic insulin sensitivity.(15)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">The peptide's effects on hepatic glucose production were also investigated. Research suggested that tirzepatide may reduce the amount of glucose produced by the liver, potentially contributing to overall glucose regulation.(7)\u003C\u002Fp>\n\u003Ch3 class=\"font-claude-response-subheading text-text-100 mt-1 -mb-1.5\">Tirzepatide Peptide and Energy Metabolism\u003C\u002Fh3>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Research examining energy metabolism suggested that tirzepatide may influence both energy intake and energy expenditure. Studies indicated the compound's primary mechanism for weight reduction appeared to involve reduced food intake, though additional mechanisms including increased energy expenditure have been hypothesized.(20)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Investigations into adipose tissue effects suggested that GIP receptor activation may influence insulin sensitivity in adipocytes. Research indicated that tirzepatide may enhance insulin-stimulated glucose deposition in skeletal muscle and adipose tissue, suggesting improved metabolic efficiency.(15)\u003C\u002Fp>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Studies examining white and brown adipose tissue suggested that the GIP component of tirzepatide may play a role in dietary triglyceride clearance and lipid storage regulation. Research in animal models indicated improvements in lipid handling in adipose tissue with tirzepatide administration.(15)\u003C\u002Fp>\n\u003Ch2 class=\"font-claude-response-heading text-text-100 mt-1 -mb-0.5\">Available for Research Purposes Only\u003C\u002Fh2>\n\u003Cp class=\"font-claude-response-body break-words whitespace-normal \">Tirzepatide peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.\u003C\u002Fp>\n\u003Chr class=\"border-border-300 my-4\" \u002F>\n\u003Ch2 class=\"font-claude-response-heading text-text-100 mt-1 -mb-0.5\">References\u003C\u002Fh2>\n\u003Col class=\"[&:not(:last-child)_ul]:pb-1 [&:not(:last-child)_ol]:pb-1 list-decimal space-y-2.5 pl-7\">\n\u003Cli class=\"whitespace-normal break-words\">Frias JP. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. Expert Rev Endocrinol Metab. 2020;15(6):379-394. \u003Ca class=\"underline\" href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F33030356\u002F\">https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F33030356\u002F\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli class=\"whitespace-normal break-words\">Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. \u003Ca class=\"underline\" href=\"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2206038\">https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Ffull\u002F10.1056\u002FNEJMoa2206038\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli class=\"whitespace-normal break-words\">Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021;106(2):388-396. \u003Ca class=\"underline\" href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F33236115\u002F\">https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F33236115\u002F\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli class=\"whitespace-normal break-words\">Heise T, Mari A, DeVries JH, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care. 2023;46(2):998-1004.\u003C\u002Fli>\n\u003Cli class=\"whitespace-normal break-words\">Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155.\u003C\u002Fli>\n\u003Cli class=\"whitespace-normal break-words\">Campbell JE, Ussher JR, Mulvihill EE, et al. TCF1 links GIPR signaling to the control of beta cell function and survival. Nat Med. 2016;22(1):84-90. \u003Ca class=\"underline\" href=\"https:\u002F\u002Fcorporate.dukehealth.org\u002Fnews\u002Ftirzepatide-has-unique-activity-stimulate-insulin-secretion\">https:\u002F\u002Fcorporate.dukehealth.org\u002Fnews\u002Ftirzepatide-has-unique-activity-stimulate-insulin-secretion\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli class=\"whitespace-normal break-words\">Wilson JM, Lin Y, Fu H, et al. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis. Diabetes Obes Metab. 2022;24(1):148-153.\u003C\u002Fli>\n\u003Cli class=\"whitespace-normal break-words\">Dahl D, Onishi Y, Norwood P, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534-545.\u003C\u002Fli>\n\u003Cli class=\"whitespace-normal break-words\">Brown KL, Frias JP, Maldonado JM, et al. Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1). J Endocr Soc. 2023;7(5):bvad056. \u003Ca class=\"underline\" href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37153701\u002F\">https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37153701\u002F\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli class=\"whitespace-normal break-words\">Frias JP, De Block C, Brown K, et al. Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2). J Clin Endocrinol Metab. 2024;109(7):1745-1752.\u003C\u002Fli>\n\u003Cli class=\"whitespace-normal break-words\">Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021;106(2):388-396. \u003Ca class=\"underline\" href=\"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC7823251\u002F\">https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC7823251\u002F\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli class=\"whitespace-normal break-words\">Cho YK, Lee YL, Jung CH. The cardiovascular effect of tirzepatide: a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide dual agonist. J Lipid Atheroscler. 2023;12(3):213-222. \u003Ca class=\"underline\" href=\"https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC10548186\u002F\">https:\u002F\u002Fpmc.ncbi.nlm.nih.gov\u002Farticles\u002FPMC10548186\u002F\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli class=\"whitespace-normal break-words\">Wharton S, Davies M, Dicker D, et al. The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2024;13(24):7833. \u003Ca class=\"underline\" href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F39681390\u002F\">https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F39681390\u002F\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli class=\"whitespace-normal break-words\">Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626.\u003C\u002Fli>\n\u003Cli class=\"whitespace-normal break-words\">Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14.\u003C\u002Fli>\n\u003Cli class=\"whitespace-normal break-words\">Patoulias D, Papadopoulos C, Fragakis N, Doumas M. Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol. 2023;82(5):333-339. \u003Ca class=\"underline\" href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37700437\u002F\">https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F37700437\u002F\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli class=\"whitespace-normal break-words\">Hankosky ER, Wang H, Neff LM, et al. Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis. Diabetes Obes Metab. 2024;26(3):1099-1109.\u003C\u002Fli>\n\u003Cli class=\"whitespace-normal break-words\">Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591-598.\u003C\u002Fli>\n\u003Cli class=\"whitespace-normal break-words\">Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-1824.\u003C\u002Fli>\n\u003Cli class=\"whitespace-normal break-words\">Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515.\u003C\u002Fli>\n\u003C\u002Fol>\n","TLP-TIRZ-20MG","90",23,[],{"length":59,"width":59,"height":59},[],[],[660],{"id":78,"name":79,"slug":80},[],[663],{"id":664,"name":647,"slug":648},77,[666,667],{"id":85,"date_created":86,"date_created_gmt":86,"date_modified":87,"date_modified_gmt":87,"src":88,"name":89,"alt":59,"srcset":90,"sizes":91,"thumbnail":92},{"id":668,"date_created":669,"date_created_gmt":669,"date_modified":87,"date_modified_gmt":87,"src":670,"name":671,"alt":59,"srcset":672,"sizes":483,"thumbnail":673},3048,"2026-02-03T22:47:55","https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fc696d4a2df2e2a89c2ad.png","c696d4a2df2e2a89c2ad","https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fc696d4a2df2e2a89c2ad-200x295.png 200w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fc696d4a2df2e2a89c2ad-203x300.png 203w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fc696d4a2df2e2a89c2ad-400x590.png 400w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fc696d4a2df2e2a89c2ad-500x738.png 500w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fc696d4a2df2e2a89c2ad-600x885.png 600w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fc696d4a2df2e2a89c2ad-694x1024.png 694w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fc696d4a2df2e2a89c2ad-700x1033.png 700w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fc696d4a2df2e2a89c2ad-768x1133.png 768w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fc696d4a2df2e2a89c2ad-800x1180.png 800w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fc696d4a2df2e2a89c2ad-1041x1536.png 1041w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fc696d4a2df2e2a89c2ad-1200x1770.png 1200w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fc696d4a2df2e2a89c2ad-1388x2048.png 1388w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fc696d4a2df2e2a89c2ad.png 1600w","https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fc696d4a2df2e2a89c2ad-500x738.png",[675],{"id":72,"name":95,"slug":95,"position":72,"visible":64,"variation":64,"options":676},[97,613,614,677,678],"40mg","60mg",[680],{"id":72,"name":95,"option":613},[682],3058,[],"\u003Cspan class=\"woocommerce-Price-amount amount\">\u003Cbdi>\u003Cspan class=\"woocommerce-Price-currencySymbol\">$\u003C\u002Fspan>90.00\u003C\u002Fbdi>\u003C\u002Fspan>",[107,105,50,106,108],[687,690,693,695,697,699],{"id":688,"key":127,"value":689},8971,{"slider_visibility":129,"slider_type":70,"wooslider":130,"page_title_bar":131},{"id":691,"key":134,"value":692},8972,"121",{"id":694,"key":138,"value":114},8973,{"id":696,"key":141,"value":142},8974,{"id":698,"key":113,"value":114},9547,{"id":700,"key":145,"value":701},9548,"23",{"self":703,"collection":708},[704],{"href":705,"targetHints":706},"https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-json\u002Fwc\u002Fv3\u002Fproducts\u002F2826",{"allow":707},[156,157,158,159,160],[709],{"href":163},{"id":107,"name":711,"slug":712,"permalink":713,"date_created":714,"date_created_gmt":714,"date_modified":715,"date_modified_gmt":715,"type":56,"status":57,"featured":22,"catalog_visibility":58,"description":716,"short_description":60,"sku":717,"price":718,"regular_price":59,"sale_price":59,"date_on_sale_from":63,"date_on_sale_from_gmt":63,"date_on_sale_to":63,"date_on_sale_to_gmt":63,"on_sale":22,"purchasable":64,"total_sales":719,"virtual":22,"downloadable":22,"downloads":720,"download_limit":67,"download_expiry":67,"external_url":59,"button_text":59,"tax_status":68,"tax_class":59,"manage_stock":64,"stock_quantity":721,"backorders":722,"backorders_allowed":64,"backordered":22,"low_stock_amount":63,"sold_individually":22,"weight":59,"dimensions":723,"shipping_required":64,"shipping_taxable":64,"shipping_class":59,"shipping_class_id":72,"reviews_allowed":64,"average_rating":73,"rating_count":72,"upsell_ids":724,"cross_sell_ids":725,"parent_id":72,"purchase_note":59,"categories":726,"brands":728,"tags":729,"images":732,"attributes":741,"default_attributes":744,"variations":746,"grouped_products":748,"menu_order":72,"price_html":749,"related_ids":750,"meta_data":751,"stock_status":149,"has_options":64,"post_password":59,"global_unique_id":59,"jetpack_sharing_enabled":64,"_links":766},"Semaglutide","semaglutide","https:\u002F\u002Fapi.tlpeptides.com\u002Fproduct\u002Fsemaglutide\u002F","2025-12-02T03:42:14","2026-05-21T19:38:05","\u003Ch2>Semaglutide Peptide\u003C\u002Fh2>\n\u003Cp>Semaglutide is a synthetic peptide that has been investigated in various research studies for its potential effects on glucose metabolism, body weight regulation, and cardiovascular parameters. The compound functions as a glucagon-like peptide-1 (GLP-1) receptor agonist with an extended half-life profile.\u003C\u002Fp>\n\u003Cp>Semaglutide is a synthetic analog of human GLP-1 composed of 31 amino acids with structural modifications designed to enhance pharmacokinetic properties. The peptide is approximately 94% homologous to native GLP-1 and incorporates specific amino acid substitutions to resist enzymatic degradation.(1)\u003C\u002Fp>\n\u003Ch2>Overview\u003C\u002Fh2>\n\u003Cp>Semaglutide has been investigated for its potential in metabolic regulation through its GLP-1 receptor agonism mechanism. Studies suggest that the peptide may stimulate insulin secretion from pancreatic beta cells in a glucose-dependent manner while modulating glucagon release. The compound appears to bind with GLP-1 receptors expressed throughout various tissues, potentially initiating signaling cascades that influence metabolic function.(2)\u003C\u002Fp>\n\u003Cp>Research has explored semaglutide's action across multiple physiological pathways. The peptide has been studied for its potential effects on glucose homeostasis, body weight regulation, appetite control, and cardiovascular function. Laboratory investigations indicate the compound may influence energy balance through both central and peripheral mechanisms.(3)\u003C\u002Fp>\n\u003Cp>Studies have suggested the peptide may enhance beta-cell function and improve markers of insulin sensitivity. The GLP-1 receptor activation appears to provide effects on glucose-dependent insulin secretion, appetite regulation through central pathways, and modulation of gastric motility.(4)\u003C\u002Fp>\n\u003Ch2>Chemical Makeup\u003C\u002Fh2>\n\u003Cp>\u003Cstrong>Molecular Formula:\u003C\u002Fstrong> C187H291N45O59\u003Cbr \u002F>\n\u003Cstrong>Molecular Weight:\u003C\u002Fstrong> 4113.58 g\u002Fmol\u003Cbr \u002F>\n\u003Cstrong>Other Known Titles:\u003C\u002Fstrong> GLP-1 analog, NN9535\u003C\u002Fp>\n\u003Ch2>Research and Clinical Studies\u003C\u002Fh2>\n\u003Ch3>Semaglutide Peptide and Glucose Metabolism\u003C\u002Fh3>\n\u003Cp>In research studies examining metabolic function, semaglutide was investigated for its potential effects on glucose regulation and insulin secretion. The compound appeared to enhance glucose-dependent insulin secretion, suggesting it may preferentially stimulate insulin release when blood glucose levels are elevated while maintaining a low risk of hypoglycemia during normoglycemic conditions.(5)\u003C\u002Fp>\n\u003Cp>Studies utilizing intravenous glucose tolerance tests indicated that semaglutide administration appeared to increase both first- and second-phase insulin secretion. Research suggested that first-phase insulin response increased approximately threefold, while second-phase response increased approximately twofold compared to control groups.(6)\u003C\u002Fp>\n\u003Cp>Investigations also suggested that semaglutide may reduce fasting and postprandial glucose concentrations. The peptide appeared to decrease glucagon levels in a glucose-dependent manner, potentially contributing to improved glucose regulation. Research indicated that 24-hour meal tests showed reduced overall glucose responses with semaglutide administration.(6)\u003C\u002Fp>\n\u003Ch3>Semaglutide Peptide and Beta-Cell Function\u003C\u002Fh3>\n\u003Cp>A study examining beta-cell function markers in research models with type 2 diabetes investigated semaglutide's potential effects on pancreatic beta-cell responsiveness. The research suggested that maximal insulin secretory capacity appeared to increase following semaglutide treatment, as demonstrated through arginine stimulation tests under hyperglycemic conditions.(7)\u003C\u002Fp>\n\u003Cp>Researchers observed that semaglutide administration appeared to improve insulin secretion rates during graded glucose infusion tests. The compound appeared to increase beta-cell responsiveness to levels comparable to those observed in healthy research participants, suggesting potential protective or restorative effects on beta-cell function.(7)\u003C\u002Fp>\n\u003Cp>Research evaluating homeostatic model assessment indices suggested that semaglutide may improve HOMA-B (beta-cell function) while decreasing HOMA-IR (insulin resistance). Studies indicated that fasting proinsulin-to-insulin ratios, which are typically elevated in models with type 2 diabetes, appeared to decrease significantly with semaglutide treatment, supporting potential improvements in beta-cell function.(8)\u003C\u002Fp>\n\u003Cp>Investigations into the molecular mechanisms suggested that semaglutide may enhance glucose-dependent insulin biosynthesis and secretion through cAMP-dependent protein kinase A pathways. Research indicated the peptide may activate signaling pathways including PI3K\u002FPKA\u002FmTOR in beta cells, potentially promoting insulin synthesis and secretion.(9)\u003C\u002Fp>\n\u003Ch3>Semaglutide Peptide and Appetite Regulation\u003C\u002Fh3>\n\u003Cp>Studies investigating appetite and energy intake suggested that semaglutide may reduce food consumption through multiple mechanisms. Research utilizing ad libitum meal tests indicated that semaglutide appeared to reduce energy intake by 24-39% compared to control groups across various study durations and doses.(10)\u003C\u002Fp>\n\u003Cp>Investigations examining participant-reported appetite ratings suggested that semaglutide may reduce hunger while increasing sensations of fullness and satiety. Research indicated improvements in overall appetite suppression scores, with participants reporting reduced prospective food consumption and better control of eating.(11)\u003C\u002Fp>\n\u003Cp>Studies exploring food preferences and cravings suggested that semaglutide may influence hedonic aspects of eating behavior. Research indicated that the compound appeared to reduce food cravings and alter preferences, with participants showing lower relative preference for high-fat, energy-dense foods.(12)\u003C\u002Fp>\n\u003Cp>Central nervous system research suggested that GLP-1 receptors in brain regions involved in appetite regulation may mediate semaglutide's effects on food intake. Studies indicated that the compound may access specific areas of the hypothalamus and brainstem, regions critical for controlling hunger and satiety.(13)\u003C\u002Fp>\n\u003Ch3>Semaglutide Peptide and Body Weight Regulation\u003C\u002Fh3>\n\u003Cp>Research examining body weight changes suggested that semaglutide may influence weight through reduced energy intake as a primary mechanism. Long-term investigations spanning 68-208 weeks indicated substantial body weight reductions ranging from 9.8% to 15.2% depending on the dose and duration of administration.(14)\u003C\u002Fp>\n\u003Cp>Studies examining body composition suggested that semaglutide-induced weight loss appeared to derive predominantly from body fat mass rather than lean mass. Research indicated approximately a threefold greater reduction in fat mass compared to lean body mass, suggesting preferential fat loss.(12)\u003C\u002Fp>\n\u003Cp>Investigations into weight loss sustainability suggested that reductions continued over extended periods. Research indicated that weight loss plateaus were reached around 60-65 weeks of treatment, with sustained reductions maintained for up to 4 years in long-term studies.(15)\u003C\u002Fp>\n\u003Ch3>Semaglutide Peptide and Gastric Emptying\u003C\u002Fh3>\n\u003Cp>Research examining gastric motility suggested complex temporal patterns of semaglutide's effects on gastric emptying. Initial studies indicated potential delays in gastric emptying after early doses, though longer-term investigations suggested these effects may diminish over time, potentially due to tachyphylaxis.(16)\u003C\u002Fp>\n\u003Cp>Studies utilizing paracetamol absorption tests as indirect measures of gastric emptying reported variable findings depending on treatment duration. Research indicated that while some early-phase delays were observed, longer treatment periods (20 weeks) showed minimal to no significant delays in overall gastric emptying when assessed over 5-hour periods.(17)\u003C\u002Fp>\n\u003Cp>Investigations in specific populations suggested that gastric emptying delays may persist in some contexts. Research in models with polycystic ovary syndrome indicated that semaglutide retained approximately 37% of solid meal content in the stomach after 4 hours compared to no retention in control groups.(18)\u003C\u002Fp>\n\u003Ch3>Semaglutide Peptide and Cardiovascular Outcomes\u003C\u002Fh3>\n\u003Cp>Research examining cardiovascular parameters suggested that semaglutide may influence multiple markers relevant to cardiovascular health. Large-scale investigations including the SUSTAIN and SELECT trials evaluated cardiovascular outcomes in diverse populations.(19)\u003C\u002Fp>\n\u003Cp>The SUSTAIN-6 trial, conducted in research models with type 2 diabetes at high cardiovascular risk, suggested that semaglutide may reduce the rate of major adverse cardiovascular events. Research indicated significantly lower rates of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke compared to control groups.(20)\u003C\u002Fp>\n\u003Cp>The SELECT trial, investigating participants with overweight or obesity and established cardiovascular disease but without diabetes, suggested that semaglutide may reduce cardiovascular risk in non-diabetic populations. Research indicated a 20% reduction in major adverse cardiovascular events, with hazard ratios of 0.80 for the primary composite endpoint.(21)\u003C\u002Fp>\n\u003Cp>Investigations suggested that cardiovascular benefits appeared independent of baseline glycemic status. Research analyzing outcomes by baseline HbA1c levels indicated consistent cardiovascular risk reduction across the entire glycemic spectrum, including normoglycemic participants.(22)\u003C\u002Fp>\n\u003Cp>Studies examining the relationship between weight loss and cardiovascular outcomes suggested that benefits may extend beyond adiposity reduction alone. Research indicated that cardiovascular event reductions emerged early in trials, potentially suggesting mechanisms beyond weight loss magnitude.(23)\u003C\u002Fp>\n\u003Ch3>Semaglutide Peptide and Lipid Metabolism\u003C\u002Fh3>\n\u003Cp>Research examining lipid parameters suggested that semaglutide may influence various aspects of lipid metabolism. Studies indicated potential reductions in total cholesterol, LDL cholesterol, and triglyceride levels with semaglutide administration.(24)\u003C\u002Fp>\n\u003Cp>Investigations suggested that systolic and diastolic blood pressure measurements appeared to decrease with semaglutide treatment. Research indicated clinically meaningful reductions in blood pressure that may contribute to overall cardiovascular risk reduction.(19)\u003C\u002Fp>\n\u003Cp>Studies examining inflammatory markers suggested that semaglutide may influence pro-inflammatory cytokine levels. Research indicated potential reductions in markers of oxidative stress and inflammation, though the mechanisms underlying these effects require further investigation.(9)\u003C\u002Fp>\n\u003Ch3>Semaglutide Peptide and Renal Function\u003C\u002Fh3>\n\u003Cp>Research examining kidney function markers suggested that semaglutide may influence renal parameters. Studies indicated potential improvements in albuminuria and other markers of kidney function in research models with diabetes and chronic kidney disease.(25)\u003C\u002Fp>\n\u003Cp>Investigations suggested that semaglutide may reduce the risk of clinically important kidney outcomes. Research indicated potential benefits on composite renal endpoints including sustained decline in estimated glomerular filtration rate, progression to end-stage kidney disease, and death from kidney-related causes.(25)\u003C\u002Fp>\n\u003Ch3>Semaglutide Peptide and Hepatic Parameters\u003C\u002Fh3>\n\u003Cp>Studies investigating liver function suggested that semaglutide may influence hepatic fat content and related parameters. Research indicated potential reductions in markers associated with metabolic dysfunction-associated steatotic liver disease.(26)\u003C\u002Fp>\n\u003Cp>Investigations examining liver enzymes suggested that semaglutide may improve transaminase levels in research models with elevated baseline values. Studies indicated improvements in hepatic steatosis markers and potential benefits for liver health.(26)\u003C\u002Fp>\n\u003Ch3>Semaglutide Peptide and Tissue-Specific Effects\u003C\u002Fh3>\n\u003Cp>Research examining adipose tissue suggested that semaglutide may modulate white adipose tissue browning processes. Studies indicated potential upregulation of uncoupling protein 1 (UCP1) and other markers associated with thermogenic activity, though most supporting evidence derives from preclinical models.(9)\u003C\u002Fp>\n\u003Cp>Investigations into skeletal muscle suggested that semaglutide may influence glucose transport through AMPK\u002FSIRT1 activation and GLUT4 upregulation. Research indicated potential effects on mitochondrial biogenesis and anti-inflammatory pathways in muscle tissue.(9)\u003C\u002Fp>\n\u003Cp>Studies examining autophagy regulation suggested that semaglutide may influence cellular quality control mechanisms. Research indicated potential activation of autophagy pathways and upregulation of transcriptional responses to oxidative stress.(9)\u003C\u002Fp>\n\u003Ch3>Semaglutide Peptide and Molecular Signaling\u003C\u002Fh3>\n\u003Cp>Research investigating intracellular signaling pathways suggested that semaglutide activates multiple downstream cascades following GLP-1 receptor binding. Studies indicated that the compound may increase intracellular cyclic AMP levels through adenylate cyclase activation.(27)\u003C\u002Fp>\n\u003Cp>Investigations suggested that elevated cAMP levels may activate protein kinase A (PKA) and exchange protein directly activated by cAMP 2 (EPAC2). Research indicated these pathways may be essential for insulin release and beta-cell function, promoting both immediate insulin secretion and gene transcription changes that enhance beta-cell survival.(27)\u003C\u002Fp>\n\u003Cp>Studies examining cardiovascular tissues suggested that semaglutide may stimulate cardioprotective signaling pathways. Research indicated potential activation of PKG\u002FPKCε\u002FERK1\u002F2 pathways, potentially reducing ischemia-induced apoptosis in cardiomyocytes.(27)\u003C\u002Fp>\n\u003Ch2>Available for Research Purposes Only\u003C\u002Fh2>\n\u003Cp>Semaglutide peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.\u003C\u002Fp>\n\u003Chr \u002F>\n\u003Ch2>References\u003C\u002Fh2>\n\u003Col>\n\u003Cli>Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380.\u003C\u002Fli>\n\u003Cli>Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102.\u003C\u002Fli>\n\u003Cli>Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429.\u003C\u002Fli>\n\u003Cli>Aroda VR, Blonde L, Pratley RE. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Rev Endocr Metab Disord. 2022;23(5):979-994.\u003C\u002Fli>\n\u003Cli>Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol\u002Flevonorgestrel. J Clin Pharmacol. 2015;55(5):497-504.\u003C\u002Fli>\n\u003Cli>Kapitza C, Zdravkovic M, Hindsberger C, Flint A. Semaglutide improves measures of beta-cell function in subjects with type 2 diabetes. Diabetologia. 2017;60(8):1390-1399.\u003C\u002Fli>\n\u003Cli>Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610-619.\u003C\u002Fli>\n\u003Cli>Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with liraglutide and metformin, in patients with type 2 diabetes (AWARD-4): a randomised, double-blind, phase 3 trial. Lancet. 2015;385(9982):2057-2066.\u003C\u002Fli>\n\u003Cli>Pappachan JM, Fernandez CJ, Chacko EC. Spotlight on the Mechanism of Action of Semaglutide. Curr Issues Mol Biol. 2024;46(12):13939-13952.\u003C\u002Fli>\n\u003Cli>Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564.\u003C\u002Fli>\n\u003Cli>Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754-762.\u003C\u002Fli>\n\u003Cli>Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242-1251.\u003C\u002Fli>\n\u003Cli>van Bloemendaal L, IJzerman RG, Ten Kulve JS, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes. 2014;63(12):4186-4196.\u003C\u002Fli>\n\u003Cli>Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.\u003C\u002Fli>\n\u003Cli>Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30(6):1836-1844.\u003C\u002Fli>\n\u003Cli>Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525-536.\u003C\u002Fli>\n\u003Cli>Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610-619.\u003C\u002Fli>\n\u003Cli>Jensterle M, Rizzo M, Haluzik M, Janez A. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes Obes Metab. 2023;25(4):975-984.\u003C\u002Fli>\n\u003Cli>Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844.\u003C\u002Fli>\n\u003Cli>Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322.\u003C\u002Fli>\n\u003Cli>Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232.\u003C\u002Fli>\n\u003Cli>Lingvay I, Deanfield J, Kahn SE, et al. Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. Diabetes Care. 2024;47(8):1360-1369.\u003C\u002Fli>\n\u003Cli>Lincoff AM, Deanfield J, Kahn SE, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025;405(10455):935-947.\u003C\u002Fli>\n\u003Cli>Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB; PIONEER 4 investigators. Effects of semaglutide on beta-cell function and glycaemic control in participants with type 2 diabetes. Diabetologia. 2019;62(5):808-818.\u003C\u002Fli>\n\u003Cli>Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121.\u003C\u002Fli>\n\u003Cli>Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124.\u003C\u002Fli>\n\u003Cli>Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756.\u003C\u002Fli>\n\u003C\u002Fol>\n","TLP-SEMA-10MG","94",4,[],16,"yes",{"length":59,"width":59,"height":59},[],[],[727],{"id":78,"name":79,"slug":80},[],[730],{"id":731,"name":711,"slug":712},73,[733,734],{"id":85,"date_created":86,"date_created_gmt":86,"date_modified":87,"date_modified_gmt":87,"src":88,"name":89,"alt":59,"srcset":90,"sizes":91,"thumbnail":92},{"id":735,"date_created":736,"date_created_gmt":736,"date_modified":736,"date_modified_gmt":736,"src":737,"name":738,"alt":59,"srcset":739,"sizes":483,"thumbnail":740},3044,"2026-02-03T22:47:37","https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fbe166d19b503e2b5172d.png","be166d19b503e2b5172d","https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fbe166d19b503e2b5172d-200x295.png 200w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fbe166d19b503e2b5172d-203x300.png 203w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fbe166d19b503e2b5172d-400x590.png 400w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fbe166d19b503e2b5172d-500x738.png 500w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fbe166d19b503e2b5172d-600x885.png 600w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fbe166d19b503e2b5172d-694x1024.png 694w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fbe166d19b503e2b5172d-700x1033.png 700w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fbe166d19b503e2b5172d-768x1133.png 768w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fbe166d19b503e2b5172d-800x1180.png 800w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fbe166d19b503e2b5172d-1041x1536.png 1041w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fbe166d19b503e2b5172d-1200x1770.png 1200w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fbe166d19b503e2b5172d-1388x2048.png 1388w, https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fbe166d19b503e2b5172d.png 1600w","https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-content\u002Fuploads\u002F2025\u002F12\u002Fbe166d19b503e2b5172d-500x738.png",[742],{"id":72,"name":95,"slug":95,"position":72,"visible":64,"variation":64,"options":743},[97],[745],{"id":72,"name":95,"option":97},[747],2942,[],"\u003Cspan class=\"woocommerce-Price-amount amount\">\u003Cbdi>\u003Cspan class=\"woocommerce-Price-currencySymbol\">$\u003C\u002Fspan>94.00\u003C\u002Fbdi>\u003C\u002Fspan>",[320,109,194,262,193],[752,755,758,760,762,764],{"id":753,"key":127,"value":754},8839,{"slider_visibility":129,"slider_type":70,"wooslider":130,"page_title_bar":131},{"id":756,"key":134,"value":757},8841,"113",{"id":759,"key":138,"value":114},8842,{"id":761,"key":141,"value":142},8843,{"id":763,"key":145,"value":409},9689,{"id":765,"key":113,"value":114},9691,{"self":767,"collection":772},[768],{"href":769,"targetHints":770},"https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-json\u002Fwc\u002Fv3\u002Fproducts\u002F2777",{"allow":771},[156,157,158,159,160],[773],{"href":163},{"id":50,"name":51,"slug":52,"permalink":53,"date_created":54,"date_created_gmt":54,"date_modified":55,"date_modified_gmt":55,"type":56,"status":57,"featured":22,"catalog_visibility":58,"description":59,"short_description":60,"sku":61,"price":62,"regular_price":59,"sale_price":59,"date_on_sale_from":63,"date_on_sale_from_gmt":63,"date_on_sale_to":63,"date_on_sale_to_gmt":63,"on_sale":22,"purchasable":64,"total_sales":65,"virtual":22,"downloadable":22,"downloads":775,"download_limit":67,"download_expiry":67,"external_url":59,"button_text":59,"tax_status":68,"tax_class":59,"manage_stock":64,"stock_quantity":69,"backorders":70,"backorders_allowed":22,"backordered":22,"low_stock_amount":63,"sold_individually":22,"weight":59,"dimensions":776,"shipping_required":64,"shipping_taxable":64,"shipping_class":59,"shipping_class_id":72,"reviews_allowed":64,"average_rating":73,"rating_count":72,"upsell_ids":777,"cross_sell_ids":778,"parent_id":72,"purchase_note":59,"categories":779,"brands":781,"tags":782,"images":783,"attributes":785,"default_attributes":788,"variations":790,"grouped_products":816,"menu_order":72,"price_html":103,"related_ids":817,"meta_data":818,"stock_status":149,"has_options":64,"post_password":59,"global_unique_id":59,"jetpack_sharing_enabled":64,"_links":832},[],{"length":59,"width":59,"height":59},[],[],[780],{"id":78,"name":79,"slug":80},[],[],[784],{"id":85,"date_created":86,"date_created_gmt":86,"date_modified":87,"date_modified_gmt":87,"src":88,"name":89,"alt":59,"srcset":90,"sizes":91,"thumbnail":92},[786],{"id":72,"name":95,"slug":95,"position":72,"visible":64,"variation":64,"options":787},[97],[789],{"id":72,"name":95,"option":97},[791],{"id":101,"type":792,"date_created":793,"date_created_gmt":793,"date_modified":794,"date_modified_gmt":794,"description":59,"permalink":795,"sku":61,"global_unique_id":59,"price":62,"regular_price":62,"sale_price":59,"date_on_sale_from":63,"date_on_sale_from_gmt":63,"date_on_sale_to":63,"date_on_sale_to_gmt":63,"on_sale":22,"status":57,"purchasable":64,"virtual":22,"downloadable":22,"downloads":796,"download_limit":67,"download_expiry":67,"tax_status":68,"tax_class":59,"manage_stock":797,"stock_quantity":69,"stock_status":149,"backorders":70,"backorders_allowed":22,"backordered":22,"low_stock_amount":63,"weight":59,"dimensions":798,"shipping_class":59,"shipping_class_id":72,"image":799,"attributes":800,"menu_order":803,"meta_data":804,"name":97,"parent_id":50,"_links":805},"variation","2026-02-06T18:39:27","2026-02-06T18:53:49","https:\u002F\u002Fapi.tlpeptides.com\u002Fproduct\u002Fipamorelin\u002F?attribute_size=10mg",[],"parent",{"length":59,"width":59,"height":59},{"id":85,"date_created":86,"date_created_gmt":86,"date_modified":87,"date_modified_gmt":87,"src":88,"name":89,"alt":59},[801],{"id":72,"name":95,"slug":802,"option":97},"size",1,[],{"self":806,"collection":811,"up":814},[807],{"href":808,"targetHints":809},"https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-json\u002Fwc\u002Fv3\u002Fproducts\u002F3078\u002Fvariations\u002F3080",{"allow":810},[156,157,158,159,160],[812],{"href":813},"https:\u002F\u002Fapi.tlpeptides.com\u002Fwp-json\u002Fwc\u002Fv3\u002Fproducts\u002F3078\u002Fvariations",[815],{"href":153},[],[194,262,105,320,109],[819,820,821,822,823,824,825,827,828,829,830,831],{"id":112,"key":113,"value":114},{"id":116,"key":113,"value":114},{"id":118,"key":113,"value":114},{"id":120,"key":113,"value":114},{"id":122,"key":113,"value":114},{"id":124,"key":113,"value":114},{"id":126,"key":127,"value":826},{"slider_visibility":129,"slider_type":70,"wooslider":130,"page_title_bar":131},{"id":133,"key":134,"value":135},{"id":137,"key":138,"value":114},{"id":140,"key":141,"value":142},{"id":144,"key":145,"value":146},{"id":148,"key":113,"value":114},{"self":833,"collection":837},[834],{"href":153,"targetHints":835},{"allow":836},[156,157,158,159,160],[838],{"href":163},1779406645231]